<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006038</article-id><article-id pub-id-type="pmc">PMC11859330</article-id><article-id pub-id-type="doi">10.3390/ph18020224</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-18-00224</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Drug Repurposing of Voglibose, a Diabetes Medication for Skin Health</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Hyeon-Mi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3000-7989</contrib-id><name><surname>Hyun</surname><given-names>Chang-Gu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="c1-pharmaceuticals-18-00224" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Rivas</surname><given-names>Francisco</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>L&#x000f3;pez-Viota</surname><given-names>Margarita</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Gim&#x000e9;nez Mart&#x000ed;nez</surname><given-names>Rafael Jes&#x000fa;s</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-18-00224">Jeju Inside Agency and Cosmetic Science Center, Department of Chemistry and Cosmetics, Jeju National University, Jeju 63243, Republic of Korea; <email>gusal1388@naver.com</email></aff><author-notes><corresp id="c1-pharmaceuticals-18-00224"><label>*</label>Correspondence: <email>cghyun@jejunu.ac.kr</email>; Tel.: +82-64-754-1803</corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>18</volume><issue>2</issue><elocation-id>224</elocation-id><history><date date-type="received"><day>19</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>30</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>04</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background/Objectives:</bold> Voglibose, an &#x003b1;-glucosidase inhibitor commonly prescribed to manage postprandial hyperglycemia in diabetes mellitus, demonstrates potential for repurposing as an anti-melanogenic agent. This study aims to explore the inhibitory effects of voglibose on melanogenesis and elucidate its molecular mechanisms, highlighting its possible applications in treating hyperpigmentation disorders. <bold>Methods:</bold> The anti-melanogenic effects of voglibose were investigated using B16F10 melanoma cells. Cell viability, melanin content, and tyrosinase activity were assessed following voglibose treatment. Western blot analysis was performed to examine changes in melanogenic proteins and transcription factors. The role of signaling pathways, including PKA/CREB, MAPK, PI3K/AKT, and GSK3&#x003b2;/&#x003b2;-Catenin, was analyzed. Primary human skin irritation tests were conducted to evaluate the topical safety of voglibose. <bold>Results:</bold> Voglibose significantly reduced melanin synthesis and tyrosinase activity in B16F10 cells in a dose-dependent manner. Western blot analysis revealed decreased expression of MITF, TRP-1, and TRP-2, indicating the inhibition of melanogenesis. Voglibose modulated key signaling pathways, including the suppression of PKA/CREB, MAPK, and AKT activation, while restoring GSK3&#x003b2; activity to inhibit &#x003b2;-catenin stabilization. Human skin irritation tests confirmed voglibose&#x02019;s safety for topical application, showing no adverse reactions at 50 and 100 &#x003bc;M concentrations. <bold>Conclusions:</bold> Voglibose demonstrates anti-melanogenic properties through the modulation of multiple signaling pathways and the inhibition of melanin biosynthesis. Its safety profile and efficacy suggest its potential as a repurposed drug for managing hyperpigmentation and advancing cosmeceutical applications.</p></abstract><kwd-group><kwd>B16F10</kwd><kwd>drug repurposing</kwd><kwd>melanogenesis</kwd><kwd>signaling pathways</kwd><kwd>voglibose</kwd></kwd-group><funding-group><award-group><funding-source>Ministry of Trade, Industry and Energy, Korea</funding-source><award-id>R&#x00026;D, P0025332</award-id></award-group><funding-statement>This research was financially supported by the Ministry of Trade, Industry and Energy, Korea under the &#x0201c;Regional Innovation Cluster Development Program (R&#x00026;D, P0025332)&#x0201d; supervised by the Korea Institute for Advancement of Technology (KIAT).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-18-00224"><title>1. Introduction</title><p>Drug repositioning, also referred to as drug repurposing, has gained prominence as an innovative strategy to identify new therapeutic applications for existing drugs. This approach offers a significant advantage by reducing the time and costs associated with drug development. While bringing a novel chemical entity to market typically demands an average investment of USD 2&#x02013;3 billion and 10&#x02013;17 years, drug repositioning achieves comparable outcomes with approximately USD 300 million invested and within 6.5 years. Moreover, the well-established safety profiles of existing drugs significantly lower the risk of clinical failure [<xref rid="B1-pharmaceuticals-18-00224" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceuticals-18-00224" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceuticals-18-00224" ref-type="bibr">3</xref>]. Several successful cases underscore the transformative potential of drug repositioning. Sildenafil (Viagra), originally developed as an antihypertensive agent, was repurposed for erectile dysfunction, achieving worldwide acclaim. Minoxidil, initially designed for hypertension, was later found effective in treating male pattern baldness due to its hypertrichosis side effect. Similarly, baricitinib, initially approved for rheumatoid arthritis, was subsequently used to treat alopecia areata, expanding its therapeutic indications [<xref rid="B4-pharmaceuticals-18-00224" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceuticals-18-00224" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceuticals-18-00224" ref-type="bibr">6</xref>].</p><p>In dermatology and skincare, drug repositioning has also proven highly effective. Thalidomide, originally developed as a sedative, is now used for multiple myeloma and skin lesions caused by leprosy. Minocycline, an antibiotic with anti-inflammatory properties, is widely used for treating acne and other inflammatory skin conditions. Methotrexate, developed as an anticancer agent, has been repurposed to treat autoimmune diseases such as psoriasis and rheumatoid arthritis [<xref rid="B7-pharmaceuticals-18-00224" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceuticals-18-00224" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceuticals-18-00224" ref-type="bibr">9</xref>]. The potential of drug repositioning is particularly evident in developing skin-whitening agents and treatments for pigmentation disorders. These disorders arise from abnormalities in melanin synthesis or distribution, which drug repositioning can effectively address by leveraging the established safety and efficacy profiles of existing drugs. For example, nilotinib, sorafenib, and ICG-001 promote melanin synthesis, while 5-iodotubercidin inhibits it. These discoveries highlight drug repositioning as a powerful tool for managing pigmentation disorders and advancing dermatological therapies [<xref rid="B10-pharmaceuticals-18-00224" ref-type="bibr">10</xref>]. In the cosmeceuticals industry, which combines the esthetic benefits of cosmetics with the functional efficacy of pharmaceuticals, drug repositioning plays a vital role. This approach addresses various concerns, including skin whitening, wrinkle reduction, and hair growth promotion, by targeting specific molecular mechanisms and pathways of existing drugs. This strategy not only accelerates development but also minimizes costs and timelines, offering innovative solutions [<xref rid="B11-pharmaceuticals-18-00224" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceuticals-18-00224" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceuticals-18-00224" ref-type="bibr">13</xref>].</p><p>Our research group has actively explored the potential of drug repositioning and natural compounds in therapeutic development. For instance, acenocoumarol, an anticoagulant, demonstrated anti-inflammatory effects by inhibiting NF-&#x003ba;B and mitogen-activated protein kinase (MAPK) signaling pathways, reducing pro-inflammatory mediators such as nitric oxide (NO), prostaglandin E<sub>2</sub> (PGE<sub>2</sub>), and cytokines (TNF-&#x003b1;, IL-6). Miglitol, an antidiabetic drug, exhibited skin-whitening effects by suppressing melanin synthesis through PKA, MAPK, and GSK3&#x003b2;/&#x003b2;-catenin pathways. Similarly, imperatorin, a natural compound, showed promise as a preventive and therapeutic agent for pigmentary disorders by inhibiting melanogenesis. Nojirimycin also displayed significant anti-inflammatory activity through NF-&#x003ba;B and MAPK pathway inhibition, highlighting its potential for dermatological applications [<xref rid="B14-pharmaceuticals-18-00224" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceuticals-18-00224" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceuticals-18-00224" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceuticals-18-00224" ref-type="bibr">17</xref>].</p><p>Voglibose (<xref rid="pharmaceuticals-18-00224-f001" ref-type="fig">Figure 1</xref>) is a pseudo-sugar derivative of valiolamine, characterized by a unique structure that allows it to inhibit &#x003b1;-glucosidase enzymes by mimicking the transition state of the substrate. Originally developed for the management of type 2 diabetes, voglibose effectively reduces postprandial glucose levels by delaying carbohydrate digestion [<xref rid="B18-pharmaceuticals-18-00224" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceuticals-18-00224" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceuticals-18-00224" ref-type="bibr">20</xref>].</p><p>Beyond its role in glucose regulation, voglibose has been reported to exhibit anti-inflammatory and antioxidative properties, which are crucial factors in maintaining skin health and mitigating hyperpigmentation-related conditions. As a representative antidiabetic drug with inhibitory activity toward human &#x003b1;-glucosidase, voglibose has been shown to block the proper N-glycan modification of tyrosinase, leading to a dramatic reduction in tyrosinase protein levels by altering its stability and subsequently decreasing melanin production [<xref rid="B21-pharmaceuticals-18-00224" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceuticals-18-00224" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceuticals-18-00224" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceuticals-18-00224" ref-type="bibr">24</xref>]. Recent studies have revealed that &#x003b1;-glucosidase inhibitors can regulate pigmentation by modulating key melanogenic enzymes such as tyrosinase, TRP-1, and TRP-2 [<xref rid="B15-pharmaceuticals-18-00224" ref-type="bibr">15</xref>]. This suggests that the inhibition of glycosylation processes is directly linked to skin brightening and a reduction in pigmentation, highlighting voglibose as a promising candidate for pigmentation disorder treatment.</p><p>In this study, we systematically investigated the effects of voglibose on melanin biosynthesis using the B16F10 melanoma cell model. Specifically, we analyzed its regulatory mechanisms acting on key melanogenic enzymes, including tyrosinase, and various signaling pathways involved in melanogenesis to elucidate its mode of action and assess its potential application for skin pigmentation control.</p></sec><sec sec-type="results" id="sec2-pharmaceuticals-18-00224"><title>2. Results and Discussion</title><sec id="sec2dot1-pharmaceuticals-18-00224"><title>2.1. Cell Viability Assessment</title><p>In the development of functional ingredients using cell-based assays, assessing cell viability is a critical step to avoid misinterpretation of results. Reduced cell viability can lead to nonspecific effects that may be misconstrued as functional activity. To accurately evaluate the safety and efficacy of an ingredient, cell viability data must be utilized to distinguish between cytotoxic effects and genuine physiological outcomes, ensuring the scientific validation of functional ingredients [<xref rid="B25-pharmaceuticals-18-00224" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceuticals-18-00224" ref-type="bibr">26</xref>]. To establish experimental conditions for evaluating the melanin-inhibitory effects of voglibose, cell viability was assessed using the MTT assay in B16F10 cells under different plating densities and culture durations. Cells were cultured with voglibose for 24 h and 72 h, and viability was analyzed under two distinct conditions: plating 1 &#x000d7; 10<sup>5</sup> cells/well with 200 &#x003bc;M voglibose for 24 h (<xref rid="pharmaceuticals-18-00224-f002" ref-type="fig">Figure 2</xref>a) and plating 2 &#x000d7; 10<sup>4</sup> cells/well with 400 &#x003bc;M voglibose for 72 h (<xref rid="pharmaceuticals-18-00224-f002" ref-type="fig">Figure 2</xref>b). The results showed a significant effect on cell viability under both conditions, with a viability of 85.14% at 200 &#x003bc;M after 24 h and 96.06% at 400 &#x003bc;M after 72 h. The differences in cell viability indicate that both plating density and culture duration influenced cellular response to voglibose. A higher initial cell density (1 &#x000d7; 10<sup>5</sup> cells/well) with a shorter culture time (24 h) led to a more pronounced decrease in viability, whereas a lower plating density (2 &#x000d7; 10<sup>4</sup> cells/well) with an extended culture period (72 h) resulted in relatively stable viability.</p><p>These findings highlight the importance of considering plating density and incubation time when evaluating the effects of voglibose on cell viability. To ensure the validity of efficacy testing in B16F10 cells, voglibose concentrations were set to 100 &#x003bc;M or lower to prevent potential cytotoxic effects.</p></sec><sec id="sec2dot2-pharmaceuticals-18-00224"><title>2.2. Effects of Voglibose on Melanin Synthesis and Tyrosinase Activity in B16F10 Cells</title><p>B16F10 cells, a murine melanoma cell line, are widely used for melanin synthesis studies due to their key regulatory pathways, including MITF, tyrosinase, TRP-1, and TRP-2. Cell-based models are cost-effective, reproducible, and useful for studying molecular mechanisms [<xref rid="B27-pharmaceuticals-18-00224" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceuticals-18-00224" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceuticals-18-00224" ref-type="bibr">29</xref>]. Melanin content and tyrosinase activity serve as crucial indicators for evaluating melanin synthesis inhibitors. Since tyrosinase regulates the rate-limiting step in melanin production, assessing its inhibition provides insights into the mechanism of action of potential inhibitors [<xref rid="B30-pharmaceuticals-18-00224" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceuticals-18-00224" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceuticals-18-00224" ref-type="bibr">32</xref>]. Thus, the B16F10 cell model is a reliable platform for investigating the regulatory effects of samples on melanin synthesis. Accordingly, in this study, we investigated the effect of voglibose on melanin synthesis and tyrosinase activity induced by &#x003b1;-MSH (100 nM) using the B16F10 cell model. As shown in <xref rid="pharmaceuticals-18-00224-f002" ref-type="fig">Figure 2</xref>, &#x003b1;-MSH treatment increased melanin content by 39.26% compared to the untreated control. In contrast, arbutin (200 &#x003bc;M), used as a positive control, reduced melanin content by 34.53%. Voglibose treatment at concentrations of 25, 50, and 100 &#x003bc;M reduced melanin content by 24.05%, 29.65%, and 32.00%, respectively. Similarly, &#x003b1;-MSH treatment increased tyrosinase activity by 41.95% compared to the control. Arbutin (200 &#x003bc;M) decreased tyrosinase activity by 32.32%, while voglibose at concentrations of 25, 50, and 100 &#x003bc;M reduced tyrosinase activity by 14.70%, 18.01%, and 21.35%, respectively. These results indicate that voglibose inhibits both &#x003b1;-MSH-induced melanin synthesis and tyrosinase activity in a dose-dependent manner, suggesting its potential as an effective melanin synthesis inhibitor.</p></sec><sec id="sec2dot3-pharmaceuticals-18-00224"><title>2.3. The Effects of Voglibose on Melanogenic Proteins and the Expression of the Transcription Factor MITF in B16F10 Cells</title><p>Melanogenesis is a critical physiological process responsible for melanin pigment synthesis, playing a key role in pigmentation of the skin, hair, and eyes. This process is regulated by major proteins, including tyrosinase, TRP-1, and TRP-2. Tyrosinase is a key enzyme catalyzing the initial steps of melanin biosynthesis by oxidizing L-tyrosine to L-DOPA and converting it into dopaquinone. As the rate-limiting enzyme in melanin biosynthesis, tyrosinase directly influences the rate of melanin production. TRP-1 stabilizes melanin synthesis and plays an essential role in regulating the ratio of eumelanin (brown and black pigments) to pheomelanin (yellow and red pigments). Additionally, TRP-1 maintains the structural stability of melanosomes and contributes to the final structural formation of melanin. TRP-2 functions in the intermediate steps of melanin biosynthesis by converting dopachrome to 5,6-dihydroxyindole-2-carboxylic acid (DHICA), preventing oxidative damage to melanin, and providing antioxidant effects to enhance melanin stability [<xref rid="B33-pharmaceuticals-18-00224" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceuticals-18-00224" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceuticals-18-00224" ref-type="bibr">35</xref>].</p><p>In this study, the effects of voglibose on melanin content reduction, tyrosinase activity inhibition, and the expression of tyrosinase, TRP-1, and TRP-2 proteins were investigated. Western blot analysis was performed, and the results are summarized as follows: In the &#x003b1;-MSH (100 nM) treatment group, TRP-1 protein expression increased by 11.99%. However, when voglibose was administered at concentrations of 25, 50, and 100 &#x003bc;M, TRP-1 protein expression decreased by 7.45%, 16.84%, and 22.46%, respectively, compared to &#x003b1;-MSH treatment. For TRP-2, &#x003b1;-MSH (100 nM) treatment led to a 38.57% increase in protein expression. When treated with 25 &#x003bc;M voglibose, TRP-2 expression increased by 30.47% compared to &#x003b1;-MSH, whereas at 100 &#x003bc;M, it showed a 24.08% decrease. Interestingly, the results for tyrosinase protein expression were contrary to the initial hypothesis. Tyrosinase protein expression increased in a concentration-dependent manner with voglibose treatment, showing increases of 7.69%, 10.65%, and 19.60% at concentrations of 25, 50, and 100 &#x003bc;M, respectively (<xref rid="pharmaceuticals-18-00224-f003" ref-type="fig">Figure 3</xref>). However, despite the increased protein expression, tyrosinase activity was inhibited. This suggests that voglibose may interfere with post-translational modifications (e.g., glycosylation) or activation processes of tyrosinase, impairing its functional activation.</p><p>The paradoxical effects of voglibose on tyrosinase activity inhibition and protein expression increase are likely related to its glycoprotein characteristics. Tyrosinase activity, stability, and proper transport to melanosomes are regulated by N-linked glycosylation. Efficient glycosylation enables tyrosinase to maintain its active state and effectively regulate the rate-limiting step of melanin biosynthesis. In contrast, insufficient or incomplete glycosylation may lead to the accumulation or degradation of inactive tyrosinase [<xref rid="B36-pharmaceuticals-18-00224" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceuticals-18-00224" ref-type="bibr">37</xref>].</p><p>As an &#x003b1;-glucosidase inhibitor, voglibose may reduce the supply of monosaccharides (e.g., glucose-6-phosphate, mannose) required for glycosylation, thereby decreasing tyrosinase glycosylation efficiency. This can hinder tyrosinase activation and induce the accumulation of inactive enzymes [<xref rid="B24-pharmaceuticals-18-00224" ref-type="bibr">24</xref>,<xref rid="B38-pharmaceuticals-18-00224" ref-type="bibr">38</xref>,<xref rid="B39-pharmaceuticals-18-00224" ref-type="bibr">39</xref>]. Consequently, even with normal synthesis of the tyrosinase protein, reduced enzyme activity may lead to decreased melanin production. Tyrosinase relies heavily on the endoplasmic reticulum (ER) for proper protein folding and post-translational modifications. Metabolic changes induced by voglibose may cause ER stress, potentially disrupting tyrosinase folding or impairing the ER quality control system, such as chaperone proteins. This can lead to the accumulation of inactive tyrosinase in the ER or its degradation via the ER-associated degradation (ERAD) pathway [<xref rid="B40-pharmaceuticals-18-00224" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceuticals-18-00224" ref-type="bibr">41</xref>]. As a redox-sensitive enzyme, tyrosinase requires an appropriate oxidative environment for activation. Voglibose-induced &#x003b1;-glucosidase inhibition may alter cellular metabolism and affect NADPH and GSH (glutathione) levels, disrupting redox balance. This could result in reduced tyrosinase activity and decreased melanin synthesis [<xref rid="B42-pharmaceuticals-18-00224" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceuticals-18-00224" ref-type="bibr">43</xref>]. Additionally, voglibose may exhibit nonspecific effects at high concentrations, indirectly affecting glycosylation-related enzymes or protein quality control pathways, further impairing tyrosinase glycosylation and transport [<xref rid="B44-pharmaceuticals-18-00224" ref-type="bibr">44</xref>]. In conclusion, voglibose induces changes in cellular metabolism and glycosylation processes through &#x003b1;-glucosidase inhibition, leading to an imbalance between tyrosinase protein production and activation.</p><p>MITF is a key transcription factor that regulates melanin biosynthesis in melanocytes and plays a pivotal role in melanogenesis. MITF directly activates the transcription of melanin biosynthesis-related genes such as tyrosinase, TRP-1, and TRP-2, thereby promoting the melanin production process. Additionally, MITF is essential for maintaining melanocyte differentiation, proliferation, and survival, as well as regulating melanosome formation. By responding to external stimuli such as UV exposure and oxidative stress, MITF modulates melanin biosynthesis and provides robust skin protective functions. Furthermore, MITF contributes to maintaining cellular homeostasis by participating in pathways related to energy metabolism within melanocytes [<xref rid="B45-pharmaceuticals-18-00224" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceuticals-18-00224" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceuticals-18-00224" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceuticals-18-00224" ref-type="bibr">48</xref>].</p><p>Given these critical functions of MITF, excessive melanin production has been identified as a major cause of various skin disorders, including melasma, freckles, lentigines, and hyperpigmentation associated with melanin over-accumulation. Therefore, strategies aimed at reducing melanin synthesis by suppressing MITF expression and activity may represent an essential approach for developing effective melanogenesis inhibitors [<xref rid="B49-pharmaceuticals-18-00224" ref-type="bibr">49</xref>,<xref rid="B50-pharmaceuticals-18-00224" ref-type="bibr">50</xref>].</p><p>In this study, we analyzed the effects of voglibose on MITF expression and activity, and we performed Western blot analysis to elucidate the relationship between melanin production inhibition and the suppression of TRP-1 and TRP-2 protein synthesis. As shown in <xref rid="pharmaceuticals-18-00224-f003" ref-type="fig">Figure 3</xref>a,d, &#x003b1;-MSH (100 nM) treatment increased MITF expression by 41.96%. However, treatment with voglibose at concentrations of 50 &#x003bc;M and 100 &#x003bc;M resulted in a reduction in MITF expression by 8.19% and 12.46%, respectively, compared to &#x003b1;-MSH (100 nM) treatment (<xref rid="pharmaceuticals-18-00224-f003" ref-type="fig">Figure 3</xref>a,d). These results suggest that voglibose inhibits the MITF signaling pathway, thereby contributing to the suppression of TRP-1 and TRP-2 protein synthesis.</p></sec><sec id="sec2dot4-pharmaceuticals-18-00224"><title>2.4. Exploring the Anti-Melanogenic Potential of Voglibose Through Signal Pathway Modulation</title><p>Melanogenesis is a vital physiological process responsible for the pigmentation of the epidermis, follicles, and irises, achieved through melanin synthesis regulated by intricate signaling pathway interactions. This process is primarily mediated by the &#x003b1;-MSH/melanocortin 1 receptor (MC1R) pathway and is closely associated with pathways such as protein kinase A (PKA)/cAMP response element-binding protein (CREB), glycogen synthase kinase (GSK)3&#x003b2;/&#x003b2;-catenin, AKT, MAPKs, and p53 [<xref rid="B51-pharmaceuticals-18-00224" ref-type="bibr">51</xref>,<xref rid="B52-pharmaceuticals-18-00224" ref-type="bibr">52</xref>,<xref rid="B53-pharmaceuticals-18-00224" ref-type="bibr">53</xref>]. These pathways regulate the expression and activity of MITF, which controls the transcription of melanogenic genes (tyrosinase, TRP-1, TRP-2) and promotes or inhibits melanosome formation. Studies on the mechanisms regulating melanogenesis provide a foundation for treating hyperpigmentation disorders, such as melasma and freckles, caused by excessive melanin production, as well as for developing effective melanin inhibitors. In particular, understanding the molecular mechanisms centered on MITF-mediated signaling pathways can help identify novel therapeutic targets and develop functional materials to modulate melanin synthesis. This study explores the mechanisms of melanogenesis inhibition, focusing on these signaling pathways and the role of MITF [<xref rid="B54-pharmaceuticals-18-00224" ref-type="bibr">54</xref>,<xref rid="B55-pharmaceuticals-18-00224" ref-type="bibr">55</xref>,<xref rid="B56-pharmaceuticals-18-00224" ref-type="bibr">56</xref>].</p><p><xref rid="pharmaceuticals-18-00224-f004" ref-type="fig">Figure 4</xref> illustrates the results of evaluating the involvement of the GSK3&#x003b2;/&#x003b2;-catenin signaling pathway in the inhibitory effects of voglibose on melanin biosynthesis. The GSK3&#x003b2;/&#x003b2;-catenin signaling pathway plays a pivotal role in melanogenesis, where the activation of GSK3&#x003b2; induces &#x003b2;-catenin degradation, suppressing MITF expression and ultimately reducing melanin production. Conversely, the inhibition of GSK3&#x003b2; stabilizes &#x003b2;-catenin, leading to its nuclear translocation and promoting MITF transcription, thereby activating melanin synthesis [<xref rid="B57-pharmaceuticals-18-00224" ref-type="bibr">57</xref>,<xref rid="B58-pharmaceuticals-18-00224" ref-type="bibr">58</xref>,<xref rid="B59-pharmaceuticals-18-00224" ref-type="bibr">59</xref>]. Treatment with &#x003b1;-MSH (100 nM) decreased p-&#x003b2;-catenin protein expression (p-&#x003b2;-catenin/&#x003b2;-actin, % of control) by 13.68% compared to the control group, activating &#x003b2;-catenin and enhancing melanogenesis. In contrast, treatment with voglibose at concentrations of 50 and 100 &#x003bc;M increased p-&#x003b2;-catenin protein expression by 29.73% and 88.27%, respectively, compared to the &#x003b1;-MSH-treated group, demonstrating the inhibition of &#x003b2;-catenin activity. Additionally, &#x003b1;-MSH (100 nM) treatment increased &#x003b2;-catenin protein expression (&#x003b2;-catenin/&#x003b2;-actin, % of control) by 26.05% compared to the control, promoting melanogenesis. However, treatment with voglibose at concentrations of 25, 50, and 100 &#x003bc;M reduced &#x003b2;-catenin protein expression by 31.69%, 39.00%, and 63.59%, respectively, compared to the &#x003b1;-MSH-treated group, indicating that voglibose effectively inhibits melanogenesis by suppressing &#x003b2;-catenin expression. The phosphorylation status of GSK3&#x003b2;, reflected by the ratio of p-GSK3&#x003b2;/t-GSK3&#x003b2; (% of control), increased by 19.29% following &#x003b1;-MSH (100 nM) treatment compared to the control group, indicating GSK3&#x003b2; inhibition and &#x003b2;-catenin stabilization. However, voglibose treatment at 50 and 100 &#x003bc;M concentrations decreased GSK3&#x003b2; phosphorylation levels by 5.67% and 6.33%, respectively, compared to the &#x003b1;-MSH-treated group. This finding suggests that voglibose restores GSK3&#x003b2; activity, promotes &#x003b2;-catenin degradation, and suppresses melanogenesis.</p><p><xref rid="pharmaceuticals-18-00224-f005" ref-type="fig">Figure 5</xref> illustrates the results of evaluating the involvement of the PKA/CREB signaling pathway in the inhibitory effects of voglibose on melanin biosynthesis. The PKA/CREB signaling pathway is a critical regulatory mechanism in melanogenesis. &#x003b1;-MSH binds to MC1R, inducing cAMP production, which activates PKA. Activated PKA phosphorylates CREB, promoting the transcription of MITF and inducing the expression of melanogenic enzymes [<xref rid="B60-pharmaceuticals-18-00224" ref-type="bibr">60</xref>,<xref rid="B61-pharmaceuticals-18-00224" ref-type="bibr">61</xref>,<xref rid="B62-pharmaceuticals-18-00224" ref-type="bibr">62</xref>,<xref rid="B63-pharmaceuticals-18-00224" ref-type="bibr">63</xref>].</p><p>Treatment with &#x003b1;-MSH (100 nM) increased PKA phosphorylation (p-PKA/t-PKA, % of control) by 75.26% compared to the control group, promoting melanogenesis through PKA pathway activation. In contrast, voglibose treatment at concentrations of 25, 50, and 100 &#x003bc;M reduced PKA phosphorylation by 33.49%, 28.43%, and 45.57%, respectively, compared to the &#x003b1;-MSH-treated group. These findings indicate that voglibose can regulate melanogenesis by inhibiting PKA phosphorylation, thereby suppressing the PKA pathway.</p><p>Additionally, &#x003b1;-MSH (100 nM) treatment increased CREB phosphorylation (p-CREB/t-CREB, % of control) by 31.95% compared to the control group, promoting MITF transcription through CREB activation. Conversely, voglibose treatment at concentrations of 25, 50, and 100 &#x003bc;M reduced CREB phosphorylation by 10.68%, 32.98%, and 51.64%, respectively, compared to the &#x003b1;-MSH-treated group. These results suggest that voglibose contributes to the inhibition of melanogenesis by suppressing CREB phosphorylation, thereby downregulating MITF transcription. These findings demonstrate that voglibose possesses a molecular mechanism that inhibits the PKA/CREB signaling pathway activated by &#x003b1;-MSH in a concentration-dependent manner, reducing MITF expression and melanin biosynthesis.</p><p><xref rid="pharmaceuticals-18-00224-f006" ref-type="fig">Figure 6</xref> illustrates the results of evaluating the involvement of the AKT signaling pathway in the inhibitory effects of voglibose on melanin biosynthesis. AKT is a key signaling molecule in melanogenesis, regulating MITF expression and the activation of melanogenic enzymes. Activation of AKT inhibits GSK3&#x003b2;, promoting the stabilization of &#x003b2;-catenin, which in turn induces MITF transcription and stimulates melanin synthesis [<xref rid="B64-pharmaceuticals-18-00224" ref-type="bibr">64</xref>,<xref rid="B65-pharmaceuticals-18-00224" ref-type="bibr">65</xref>,<xref rid="B66-pharmaceuticals-18-00224" ref-type="bibr">66</xref>]. Therefore, inhibition of the AKT signaling pathway can effectively reduce melanin production. Treatment with &#x003b1;-MSH (100 nM) increased AKT phosphorylation by 31.95% compared to the control group, activating melanogenesis. In contrast, treatment with voglibose at concentrations of 25, 50, and 100 &#x003bc;M reduced AKT phosphorylation by 11.68%, 32.98%, and 51.64%, respectively, compared to the &#x003b1;-MSH-treated group. These findings suggest that voglibose suppresses MITF activation by inhibiting the AKT signaling pathway, consequently reducing the expression of melanogenic enzymes. The downregulation of the AKT signaling pathway serves as a critical mechanism for inhibiting melanogenesis, demonstrating the potential of voglibose as an effective agent for regulating melanin biosynthesis.</p><p><xref rid="pharmaceuticals-18-00224-f007" ref-type="fig">Figure 7</xref> presents the results of evaluating the effects of voglibose on the phosphorylation of major MAPK proteins (ERK, JNK, p38) in B16F10 cells stimulated with &#x003b1;-MSH, highlighting its relationship with melanin biosynthesis inhibition. The MAPK signaling pathway is a key mechanism regulating melanin production, activated in melanocytes by external stimuli such as &#x003b1;-MSH. This pathway regulates MITF and the expression of melanogenic enzymes and consists of three sub-pathways: ERK, JNK, and p38. ERK plays an inhibitory role in melanin synthesis by promoting the degradation of MITF when activated (phosphorylated), thereby reducing the expression of melanogenic enzymes. Conversely, ERK inhibition stabilizes MITF, promoting melanin synthesis. JNK acts as a pro-melanogenic pathway, increasing MITF transcriptional activity upon activation, which induces the expression of melanogenic enzymes. This pathway is activated by stress signals or UV radiation, with increased JNK phosphorylation enhancing melanin synthesis and contributing to skin hyperpigmentation. Similarly, the p38 pathway promotes melanin synthesis by stabilizing MITF and increasing the expression of melanogenic enzymes [<xref rid="B67-pharmaceuticals-18-00224" ref-type="bibr">67</xref>,<xref rid="B68-pharmaceuticals-18-00224" ref-type="bibr">68</xref>,<xref rid="B69-pharmaceuticals-18-00224" ref-type="bibr">69</xref>,<xref rid="B70-pharmaceuticals-18-00224" ref-type="bibr">70</xref>]. Environmental stress, such as UV exposure, activates p38, and its phosphorylation enhances melanin production and skin pigmentation. The MAPK pathway functions through the interplay of ERK, JNK, and p38, where ERK suppresses melanin synthesis, while JNK and p38 promote it. This balance regulates melanogenesis and impacts conditions such as skin hyperpigmentation, vitiligo, and freckles. Modulating ERK, JNK, and p38 pathways serves as a strategic approach for developing skin-whitening agents and treatments for pigmentation disorders. The experimental results show that &#x003b1;-MSH treatment reduced ERK phosphorylation by 27.45% while increasing JNK and p38 phosphorylation by 29.85% and 11.56%, respectively. However, treatment with voglibose at 25, 50, and 100 &#x003bc;M increased ERK phosphorylation by 12.70%, 29.31%, and 32.46%, respectively, compared to the &#x003b1;-MSH-treated group. Meanwhile, voglibose reduced JNK phosphorylation by 19.61%, 29.61%, and 38.10% and p38 phosphorylation by 18.38%, 33.89%, and 46.09%, respectively. These findings indicate that voglibose inhibits the JNK and p38 signaling pathways activated by &#x003b1;-MSH, effectively suppressing melanin biosynthesis. The reduced phosphorylation of JNK and p38 likely plays a crucial role in downregulating the expression of melanogenic enzymes. In contrast, the increased ERK phosphorylation observed with voglibose treatment suggests an alternative mechanism by which voglibose promotes the degradation of MITF via ERK activation, thereby inhibiting melanin synthesis.</p></sec><sec id="sec2dot5-pharmaceuticals-18-00224"><title>2.5. Human Skin Irritation Study of Voglibose</title><p>Ensuring skin safety is a critical step in the development of functional whitening agents. First, skin safety minimizes the risk of irritation or allergic reactions, which may result from the potent chemical properties of certain whitening ingredients. By establishing safety, products can be delivered to consumers with confidence in their usability. Second, high skin safety enhances the feasibility of long-term product use. Products with proven stability are less likely to cause adverse effects over extended usage periods, contributing to increased consumer satisfaction. Third, products with demonstrated skin safety build trust among consumers, which is essential for creating a positive brand image. Reliable products not only encourage repeat purchases but also foster long-term brand loyalty. Fourth, compliance with safety regulations is a fundamental requirement for cosmetic and skincare products. Securing skin safety ensures adherence to these regulatory standards. Finally, ensuring skin safety supports the effective delivery of whitening benefits without adverse effects on the skin. As such, securing the skin safety of functional whitening agents is a vital component for product success and user satisfaction [<xref rid="B71-pharmaceuticals-18-00224" ref-type="bibr">71</xref>,<xref rid="B72-pharmaceuticals-18-00224" ref-type="bibr">72</xref>,<xref rid="B73-pharmaceuticals-18-00224" ref-type="bibr">73</xref>].</p><p>Therefore, in this study, the skin safety and potential of voglibose for topical applications were evaluated through primary human skin irritation tests. Voglibose was applied to designated skin areas at concentrations of 50 and 100 &#x003bc;M for up to 24 h. After the removal of voglibose, the application sites were observed at 20 min and 24 h post-application. Squalene, used as a solvent, served as the negative control. As summarized in <xref rid="pharmaceuticals-18-00224-t001" ref-type="table">Table 1</xref>, voglibose was classified as having &#x0201c;no to slight irritation&#x0201d; based on its primary irritation potential on human skin. These findings suggest that voglibose demonstrates minimal irritation, supporting its suitability for topical use.</p></sec></sec><sec id="sec3-pharmaceuticals-18-00224"><title>3. Materials and Methods</title><sec id="sec3dot1-pharmaceuticals-18-00224"><title>3.1. Reagents and Materials</title><p>Voglibose (&#x0003e;98.0%) was purchased from TCI Co., Ltd. (Tokyo, Japan). MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reagent, 10&#x000d7; Tris-Glycine (SDS) buffer, RIPA buffer, DMSO, PBS, and the ECL (Enhanced Chemiluminescence) kit were obtained from Biosesang Inc. (Seongnam, Gyeonggi-do, Republic of Korea). Kojic acid, L-DOPA, protease/phosphatase inhibitor cocktail, and &#x003b1;-MSH were purchased from Sigma-Aldrich Co. LLC (St. Louis, MO, USA). FBS (fetal bovine serum) was acquired from Merck KGaA (Burlington, MA, USA). DMEM (Dulbecco&#x02019;s Modified Eagle&#x02019;s Medium) and penicillin&#x02013;streptomycin (10,000 U/mL) were supplied by Thermo Fisher Scientific Inc., through its Gibco brand (Grand Island, NY, USA).</p><p>Primary antibodies included MITF (SC-71588), tyrosinase (SC-20035), TRP-1 (SC-166857), and TRP-2 (SC-74439), all purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Antibodies from Cell Signaling Technology, Inc. (Danvers, MA, USA) included CREB (D76D11) Rabbit mAb (4820S), phospho-CREB (Ser133) (87G3) Rabbit mAb (9198S), PKA and phospho-PKA C (Thr197) (D45D3) Rabbit mAb (5661S), &#x003b2;-catenin (D10A8) XP<sup>&#x000ae;</sup> Rabbit mAb (25362S), phospho-&#x003b2;-catenin (S33/37/T41) Rabbit Ab (9561S), phospho-SAPK/JNK (Thr183/Tyr185) Antibody (9251S), SAPK/JNK Rabbit Ab (9252S), p44/42 MAPK (Erk1/2) Antibody (9102S), P-p44/42 MAPK (T202/Y204) Rabbit Ab (9101S), P-p38 MAPK (T100/Y182) Rabbit Ab (9211S), p38 MAPK Rabbit Ab (9212S), phospho-GSK-3-&#x003b2; (S9) (D3A4) Rabbit mAb (9322S), GSK-3 &#x003b1;/&#x003b2; (D75D3) Rabbit mAb (5676S), Akt Rabbit Ab (9272S), phospho-Akt (S473) Rabbit Ab (9271S), and &#x003b2;-actin Rabbit Antibody (4967S).</p><p>Secondary antibodies, Anti-rabbit IgG HRP-linked Antibody (7074S) and Anti-mouse IgG HRP-linked Antibody (7076S), were also obtained from Cell Signaling Technology, Inc. The inhibitors used in this study included PD98059, an ERK inhibitor purchased from Cayman Chemical Company (Ann Arbor, MI, USA), and LY294002, an AKT inhibitor obtained from Cell Signaling Technology, Inc. Phosphorylation sites on proteins, such as phospho-CREB (Ser133), phospho-PKA C (Thr197), phospho-&#x003b2;-catenin (S33/37/T41), phospho-SAPK/JNK (Thr183/Tyr185), P-p44/42 MAPK (T202/Y204), P-p38 MAPK (T100/Y182), and phospho-GSK-3-&#x003b2; (S9), were annotated based on the respective amino acid residues.</p></sec><sec id="sec3dot2-pharmaceuticals-18-00224"><title>3.2. Cell Culture</title><p>The B16F10 murine melanoma cell line was acquired from the American Type Culture Collection (ATCC) and the Korean Cell Line Bank (KCLB). B16F10 cells were maintained at 37 &#x000b0;C in a humidified atmosphere with 5% CO<sub>2</sub>. The culture medium used was Dulbecco&#x02019;s Modified Eagle&#x02019;s Medium (DMEM; Thermo Fisher Scientific Inc., Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (10,000 U/mL).</p></sec><sec id="sec3dot3-pharmaceuticals-18-00224"><title>3.3. Cell Viability Assay</title><p>Cell viability was evaluated using the MTT assay. B16F10 cells were seeded and cultured in a 24-well plate at a density of 1.5 &#x000d7; 10<sup>4</sup> cells/well. After 24 h, voglibose was added at various concentrations (12.5, 25, 50, 100, 200, and 400 &#x003bc;M). Following a 72 h incubation period, the MTT reagent was added to each well, and the plate was incubated for less than 4 h at 37 &#x000b0;C. The absorbance was measured at 540 nm using a microplate spectrophotometer (BioTek Epoch, Agilent Technologies, Inc., Winooski, Vermont, USA).</p></sec><sec id="sec3dot4-pharmaceuticals-18-00224"><title>3.4. Melanin Content Measurement</title><p>B16F10 melanoma cells stimulated to induce melanogenesis were washed twice with cold PBS, and total proteins were extracted using RIPA buffer. The cell lysates were centrifuged at 15,000 rpm for 20 min at &#x02212;8 &#x000b0;C, and the resulting pellet was separated. The pellet was dissolved in 1 N NaOH containing 10% DMSO and incubated at 80 &#x000b0;C for 10 min. The melanin content was measured at 405 nm using a spectrophotometric microplate reader with a 96-well plate.</p></sec><sec id="sec3dot5-pharmaceuticals-18-00224"><title>3.5. Tyrosinase Activity Assay</title><p>B16F10 melanoma cells stimulated to induce melanin production were washed twice with PBS, and total proteins were extracted using RIPA buffer. The cell lysates were centrifuged at 15,000 rpm for 20 min at 4 &#x000b0;C, and the total protein concentration in the supernatant was determined using a BCA assay. For the tyrosinase activity assay, the reaction mixture consisted of 80 &#x003bc;L of cell lysate (containing 30 &#x003bc;g/mL total protein) and 20 &#x003bc;L of L-DOPA solution (2 mg/mL in 0.1 M sodium phosphate buffer, pH 6.8) in a 96-well plate. The mixture was incubated at 37 &#x000b0;C, and the production of dopaquinone was measured at 490 nm using a spectrophotometric microplate reader after 2 h.</p></sec><sec id="sec3dot6-pharmaceuticals-18-00224"><title>3.6. Western Blot Analysis</title><p>B16F10 melanoma cells treated with voglibose (25 to 100 &#x003bc;M) were harvested using RIPA buffer supplemented with a protease inhibitor cocktail. The protein concentration of the cell lysates was determined using a BCA protein assay kit and adjusted to 30 &#x003bc;g/mL. Protein samples were prepared by mixing the lysates with sample buffer (2&#x000d7; Laemmli buffer: 2-mercaptoethanol = 20:1) and heating at 100 &#x000b0;C for 5 min. Proteins were separated using Tris-Glycine SDS-polyacrylamide gel electrophoresis and transferred onto a PVDF membrane. The membrane was blocked with 5% skim milk prepared in TBS-T to prevent nonspecific binding of antibodies. After blocking, the membrane was washed with TBS-T and incubated with primary antibodies at 4 &#x000b0;C with shaking overnight. Following extensive washing with TBS-T, the membrane was incubated with secondary antibodies for 2 h. After washing with TBS-T, protein bands were visualized using the BS ECL Plus Kit (Biosesang, Seongnam, Republic of Korea) and photographed with the Chemidoc imaging system (Vilber Lourmat, France). Quantification of the detected bands was performed using ImageJ software (Version 1.54k, NIH, Bethesda, MD, USA), and the data were presented in graph form.</p></sec><sec id="sec3dot7-pharmaceuticals-18-00224"><title>3.7. Primary Skin Irritation Test</title><p>A total of 33 healthy female volunteers aged between 21 and 54 years (mean age: 43.58 &#x000b1; 9.29 years), with no history of irritant or allergic contact dermatitis, participated in this study. Squalene was used as the negative control. Voglibose was dissolved in squalene to prepare test solutions at concentrations of 50 and 100 &#x003bc;M. Primary skin irritation responses were evaluated based on the PCPC guidelines. The irritation response for squalene and voglibose in squalene was calculated using the formula provided below.<disp-formula id="FD1-pharmaceuticals-18-00224"><mml:math id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>Response</mml:mi><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mrow><mml:mo stretchy="false">&#x02211;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mo>&#x000d7;</mml:mo><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mo>.</mml:mo><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mn>4</mml:mn><mml:mo>(</mml:mo><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mo>)</mml:mo><mml:mo>&#x000d7;</mml:mo><mml:mi>n</mml:mi><mml:mo>(</mml:mo><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">j</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>This study was conducted in compliance with the ethical principles outlined in the Declaration of Helsinki and was approved by the Industrial Review Board (IRB) of Dermapro Inc. Written informed consent was obtained from all participants prior to the study (IRB number: 1-220777-A-N-01-DICN22080).</p></sec><sec id="sec3dot8-pharmaceuticals-18-00224"><title>3.8. Statistical Analysis</title><p>The experimental results are presented as the mean &#x000b1; standard deviation (SD) from three independent experiments. Statistical significance was determined using Student&#x02019;s <italic toggle="yes">t</italic>-test. The significance levels are indicated as follows: #: <italic toggle="yes">p</italic> &#x0003c; 0.001 compared to the unstimulated control group. ***: <italic toggle="yes">p</italic> &#x0003c; 0.05, **: <italic toggle="yes">p</italic> &#x0003c; 0.01, and ***: <italic toggle="yes">p</italic> &#x0003c; 0.001 compared to the group treated with &#x003b1;-MSH alone.</p></sec></sec><sec sec-type="conclusions" id="sec4-pharmaceuticals-18-00224"><title>4. Conclusions</title><p>This study explored the anti-melanogenic effects and molecular mechanisms of voglibose, highlighting its potential for repurposing as a therapeutic agent for hyperpigmentation disorders and the development of functional cosmetics. The results demonstrate that voglibose inhibited melanin synthesis and tyrosinase activity in a dose-dependent manner and reduced the expression of MITF, TRP-1, and TRP-2 proteins, effectively suppressing melanogenesis. Furthermore, voglibose modulated key signaling pathways, including PKA/CREB, MAPK, PI3K/AKT, and GSK3&#x003b2;/&#x003b2;-Catenin, and its topical safety was confirmed through human skin irritation tests. However, this study was conducted using the B16F10 melanoma cell model, and the effects of voglibose on primary human melanocytes, which provide a more physiologically relevant model for melanin biosynthesis, were not validated. Future studies are necessary to evaluate the efficacy of voglibose in primary human melanocytes and to confirm its long-term safety and effects on various skin types and with different environmental factors, such as UV exposure, through clinical trials. Additionally, further investigations should clarify the detailed molecular interactions observed in the signaling pathway analysis. Addressing these limitations will help expand the potential applications of voglibose and provide a stronger scientific foundation for its use in treating hyperpigmentation and developing functional cosmetics.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, C.-G.H.; methodology, H.-M.K.; validation, H.-M.K.; formal analysis, H.-M.K.; writing&#x02014;original draft preparation, C.-G.H.; writing&#x02014;review and editing, C.-G.H.; supervision, C.-G.H.; project administration, C.-G.H.; funding acquisition, C.-G.H. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of Dermapro Ltd. (Seoul, Republic of Korea). for studies involving humans (IRB number: 1-220777-A-N-01-DICN22080).</p></notes><notes><title>Informed Consent Statement</title><p>All participants involved in this study provided written informed consent.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All data generated or analyzed during this study are fully available within this published article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceuticals-18-00224"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mishra</surname><given-names>A.S.</given-names></name>
<name><surname>Vasanthan</surname><given-names>M.</given-names></name>
<name><surname>Malliappan</surname><given-names>S.P.</given-names></name>
</person-group><article-title>Drug Repurposing: A Leading Strategy for New Threats and Targets</article-title><source>ACS Pharmacol. Transl. Sci.</source><year>2024</year><volume>7</volume><fpage>915</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1021/acsptsci.3c00361</pub-id><pub-id pub-id-type="pmid">38633585</pub-id>
</element-citation></ref><ref id="B2-pharmaceuticals-18-00224"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weth</surname><given-names>F.R.</given-names></name>
<name><surname>Hoggarth</surname><given-names>G.B.</given-names></name>
<name><surname>Weth</surname><given-names>A.F.</given-names></name>
<name><surname>Paterson</surname><given-names>E.</given-names></name>
<name><surname>White</surname><given-names>M.P.J.</given-names></name>
<name><surname>Tan</surname><given-names>S.T.</given-names></name>
<name><surname>Peng</surname><given-names>L.</given-names></name>
<name><surname>Gray</surname><given-names>C.</given-names></name>
</person-group><article-title>Unlocking hidden potential: Advancements, approaches, and obstacles in repurposing drugs for cancer therapy</article-title><source>Br. J. Cancer.</source><year>2024</year><volume>130</volume><fpage>703</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1038/s41416-023-02502-9</pub-id><pub-id pub-id-type="pmid">38012383</pub-id>
</element-citation></ref><ref id="B3-pharmaceuticals-18-00224"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ng</surname><given-names>Y.L.</given-names></name>
<name><surname>Salim</surname><given-names>C.K.</given-names></name>
<name><surname>Chu</surname><given-names>J.J.H.</given-names></name>
</person-group><article-title>Drug repurposing for COVID-19: Approaches, challenges and promising candidates</article-title><source>Pharmacol. Ther.</source><year>2021</year><volume>228</volume><fpage>107930</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2021.107930</pub-id><pub-id pub-id-type="pmid">34174275</pub-id>
</element-citation></ref><ref id="B4-pharmaceuticals-18-00224"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jackson</surname><given-names>G.</given-names></name>
<name><surname>Gillies</surname><given-names>H.</given-names></name>
<name><surname>Osterloh</surname><given-names>I.</given-names></name>
</person-group><article-title>Past, present, and future: A 7-year update of Viagra (sildenafil citrate)</article-title><source>Int. J. Clin. Pract.</source><year>2005</year><volume>59</volume><fpage>680</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1111/j.1368-5031.2005.00578.x</pub-id><pub-id pub-id-type="pmid">15924597</pub-id>
</element-citation></ref><ref id="B5-pharmaceuticals-18-00224"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>York</surname><given-names>K.</given-names></name>
<name><surname>Meah</surname><given-names>N.</given-names></name>
<name><surname>Bhoyrul</surname><given-names>B.</given-names></name>
<name><surname>Sinclair</surname><given-names>R.</given-names></name>
</person-group><article-title>A review of the treatment of male pattern hair loss</article-title><source>Expert Opin. Pharmacother.</source><year>2020</year><volume>21</volume><fpage>603</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1080/14656566.2020.1721463</pub-id><pub-id pub-id-type="pmid">32066284</pub-id>
</element-citation></ref><ref id="B6-pharmaceuticals-18-00224"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Qi</surname><given-names>F.</given-names></name>
<name><surname>Dong</surname><given-names>J.</given-names></name>
<name><surname>Tan</surname><given-names>Y.</given-names></name>
<name><surname>Gao</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>F.</given-names></name>
</person-group><article-title>Application of Baricitinib in Dermatology</article-title><source>J. Inflamm. Res.</source><year>2022</year><volume>15</volume><fpage>1935</fpage><lpage>1941</lpage><pub-id pub-id-type="doi">10.2147/JIR.S356316</pub-id><pub-id pub-id-type="pmid">35330989</pub-id>
</element-citation></ref><ref id="B7-pharmaceuticals-18-00224"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ridings</surname><given-names>J.E.</given-names></name>
</person-group><article-title>The thalidomide disaster, lessons from the past</article-title><source>Methods Mol. Biol.</source><year>2013</year><volume>947</volume><fpage>575</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1007/978-1-62703-131-8_36</pub-id><pub-id pub-id-type="pmid">23138926</pub-id>
</element-citation></ref><ref id="B8-pharmaceuticals-18-00224"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martins</surname><given-names>A.M.</given-names></name>
<name><surname>Marto</surname><given-names>J.M.</given-names></name>
<name><surname>Johnson</surname><given-names>J.L.</given-names></name>
<name><surname>Graber</surname><given-names>E.M.</given-names></name>
</person-group><article-title>A Review of Systemic Minocycline Side Effects and Topical Minocycline as a Safer Alternative for Treating Acne and Rosacea</article-title><source>Antibiotics</source><year>2021</year><volume>10</volume><elocation-id>757</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics10070757</pub-id><pub-id pub-id-type="pmid">34206485</pub-id>
</element-citation></ref><ref id="B9-pharmaceuticals-18-00224"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hsieh</surname><given-names>T.S.</given-names></name>
<name><surname>Tsai</surname><given-names>T.F.</given-names></name>
</person-group><article-title>Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review</article-title><source>Dermatol. Ther.</source><year>2023</year><volume>13</volume><fpage>891</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1007/s13555-023-00903-5</pub-id><pub-id pub-id-type="pmid">36943580</pub-id>
</element-citation></ref><ref id="B10-pharmaceuticals-18-00224"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jeong</surname><given-names>S.M.</given-names></name>
<name><surname>Yoon</surname><given-names>T.J.</given-names></name>
</person-group><article-title>Development of Pigmentation-Regulating Agents by Drug Repositioning</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>3894</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22083894</pub-id><pub-id pub-id-type="pmid">33918792</pub-id>
</element-citation></ref><ref id="B11-pharmaceuticals-18-00224"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sotiropoulou</surname><given-names>G.</given-names></name>
<name><surname>Zingkou</surname><given-names>E.</given-names></name>
<name><surname>Pampalakis</surname><given-names>G.</given-names></name>
</person-group><article-title>Redirecting drug repositioning to discover innovative cosmeceuticals</article-title><source>Exp. Dermatol.</source><year>2021</year><volume>30</volume><fpage>628</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1111/exd.14299</pub-id><pub-id pub-id-type="pmid">33544970</pub-id>
</element-citation></ref><ref id="B12-pharmaceuticals-18-00224"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>V.</given-names></name>
<name><surname>Mohapatra</surname><given-names>S.</given-names></name>
<name><surname>Mishra</surname><given-names>H.</given-names></name>
<name><surname>Farooq</surname><given-names>U.</given-names></name>
<name><surname>Kumar</surname><given-names>K.</given-names></name>
<name><surname>Ansari</surname><given-names>M.J.</given-names></name>
<name><surname>Aldawsari</surname><given-names>M.F.</given-names></name>
<name><surname>Alalaiwe</surname><given-names>A.S.</given-names></name>
<name><surname>Mirza</surname><given-names>M.A.</given-names></name>
<name><surname>Iqbal</surname><given-names>Z.</given-names></name>
</person-group><article-title>Nanotechnology in Cosmetics and Cosmeceuticals-A Review of Latest Advancements</article-title><source>Gels</source><year>2022</year><volume>8</volume><elocation-id>173</elocation-id><pub-id pub-id-type="doi">10.3390/gels8030173</pub-id><pub-id pub-id-type="pmid">35323286</pub-id>
</element-citation></ref><ref id="B13-pharmaceuticals-18-00224"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barraza</surname><given-names>G.A.</given-names></name>
<name><surname>Castro-Guijarro</surname><given-names>A.C.</given-names></name>
<name><surname>de la Fuente Hoffmann</surname><given-names>V.</given-names></name>
<name><surname>Bol&#x000ed;var &#x000c1;vila</surname><given-names>S.J.</given-names></name>
<name><surname>Flamini</surname><given-names>M.I.</given-names></name>
<name><surname>Sanchez</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Drug repositioning for rosacea disease: Biological TARGET identification, molecular docking, pharmacophore mapping, and molecular dynamics analysis</article-title><source>Comput. Biol. Med.</source><year>2024</year><volume>181</volume><elocation-id>108988</elocation-id><pub-id pub-id-type="doi">10.1016/j.compbiomed.2024.108988</pub-id><pub-id pub-id-type="pmid">39168013</pub-id>
</element-citation></ref><ref id="B14-pharmaceuticals-18-00224"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Han</surname><given-names>H.J.</given-names></name>
<name><surname>Hyun</surname><given-names>C.G.</given-names></name>
</person-group><article-title>Acenocoumarol Exerts Anti-Inflammatory Activity via the Suppression of NF-&#x003ba;B and MAPK Pathways in RAW 264.7 Cells</article-title><source>Molecules</source><year>2023</year><volume>28</volume><elocation-id>2075</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28052075</pub-id><pub-id pub-id-type="pmid">36903321</pub-id>
</element-citation></ref><ref id="B15-pharmaceuticals-18-00224"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>H.M.</given-names></name>
<name><surname>Hyun</surname><given-names>C.G.</given-names></name>
</person-group><article-title>Miglitol, an Oral Antidiabetic Drug, Downregulates Melanogenesis in B16F10 Melanoma Cells through the PKA, MAPK, and GSK3&#x003b2;/&#x003b2;-Catenin Signaling Pathways</article-title><source>Molecules</source><year>2022</year><volume>28</volume><elocation-id>115</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28010115</pub-id><pub-id pub-id-type="pmid">36615308</pub-id>
</element-citation></ref><ref id="B16-pharmaceuticals-18-00224"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>T.</given-names></name>
<name><surname>Hyun</surname><given-names>C.G.</given-names></name>
</person-group><article-title>Imperatorin Positively Regulates Melanogenesis through Signaling Pathways Involving PKA/CREB, ERK, AKT, and GSK3&#x003b2;/&#x003b2;-Catenin</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>6512</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27196512</pub-id><pub-id pub-id-type="pmid">36235048</pub-id>
</element-citation></ref><ref id="B17-pharmaceuticals-18-00224"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hyun</surname><given-names>S.B.</given-names></name>
<name><surname>Chung</surname><given-names>Y.C.</given-names></name>
<name><surname>Hyun</surname><given-names>C.G.</given-names></name>
</person-group><article-title>Nojirimycin suppresses inflammation via regulation of NF-&#x003ba; B signaling pathways</article-title><source>Pharmazie</source><year>2020</year><volume>75</volume><fpage>637</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1691/ph.2020.0751</pub-id><pub-id pub-id-type="pmid">33303056</pub-id>
</element-citation></ref><ref id="B18-pharmaceuticals-18-00224"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khan</surname><given-names>F.</given-names></name>
<name><surname>Khan</surname><given-names>M.V.</given-names></name>
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Akhtar</surname><given-names>S.</given-names></name>
</person-group><article-title>Recent Advances in the Development of Alpha-Glucosidase and Alpha-Amylase Inhibitors in Type 2 Diabetes Management: Insights from In silico to In vitro Studies</article-title><source>Curr. Drug Targets.</source><year>2024</year><volume>25</volume><fpage>782</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.2174/0113894501313365240722100902</pub-id></element-citation></ref><ref id="B19-pharmaceuticals-18-00224"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Asano</surname><given-names>N.</given-names></name>
</person-group><article-title>Sugar-mimicking glycosidase inhibitors: Bioactivity and application</article-title><source>Cell. Mol. Life Sci.</source><year>2009</year><volume>66</volume><fpage>1479</fpage><lpage>1492</lpage><pub-id pub-id-type="doi">10.1007/s00018-008-8522-3</pub-id><pub-id pub-id-type="pmid">19132292</pub-id>
</element-citation></ref><ref id="B20-pharmaceuticals-18-00224"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Fan</surname><given-names>Y.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
</person-group><article-title>Properties and production of valienamine and its related analogues</article-title><source>Chem. Rev.</source><year>2003</year><volume>103</volume><fpage>1955</fpage><lpage>1977</lpage><pub-id pub-id-type="doi">10.1021/cr0102260</pub-id><pub-id pub-id-type="pmid">12744697</pub-id>
</element-citation></ref><ref id="B21-pharmaceuticals-18-00224"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cao</surname><given-names>X.</given-names></name>
<name><surname>Du</surname><given-names>X.</given-names></name>
<name><surname>Jiao</surname><given-names>H.</given-names></name>
<name><surname>An</surname><given-names>Q.</given-names></name>
<name><surname>Chen</surname><given-names>R.</given-names></name>
<name><surname>Fang</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Yu</surname><given-names>B.</given-names></name>
</person-group><article-title>Carbohydrate-based drugs launched during 2000&#x02013;2021</article-title><source>Acta Pharm. Sin. B</source><year>2022</year><volume>12</volume><fpage>3783</fpage><lpage>3821</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2022.05.020</pub-id><pub-id pub-id-type="pmid">36213536</pub-id>
</element-citation></ref><ref id="B22-pharmaceuticals-18-00224"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rajkumar</surname><given-names>M.</given-names></name>
<name><surname>Kannan</surname><given-names>S.</given-names></name>
<name><surname>Thangaraj</surname><given-names>R.</given-names></name>
</person-group><article-title>Voglibose attenuates cognitive impairment, A&#x003b2; aggregation, oxidative stress, and neuroinflammation in streptozotocin-induced Alzheimer&#x02019;s disease rat model</article-title><source>Inflammopharmacology</source><year>2023</year><volume>31</volume><fpage>2751</fpage><lpage>2771</lpage><pub-id pub-id-type="doi">10.1007/s10787-023-01313-x</pub-id><pub-id pub-id-type="pmid">37665449</pub-id>
</element-citation></ref><ref id="B23-pharmaceuticals-18-00224"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suzuki</surname><given-names>K.</given-names></name>
<name><surname>Katsura</surname><given-names>D.</given-names></name>
<name><surname>Sagara</surname><given-names>M.</given-names></name>
<name><surname>Aoki</surname><given-names>C.</given-names></name>
<name><surname>Nishida</surname><given-names>M.</given-names></name>
<name><surname>Aso</surname><given-names>Y.</given-names></name>
</person-group><article-title>Postprandial Reactive Hypoglycemia Treated with a Low-dose Alpha-glucosidase Inhibitor: Voglibose May Suppress Oxidative Stress and Prevent Endothelial Dysfunction</article-title><source>Intern. Med.</source><year>2016</year><volume>55</volume><fpage>949</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.55.5737</pub-id><pub-id pub-id-type="pmid">27086810</pub-id>
</element-citation></ref><ref id="B24-pharmaceuticals-18-00224"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bin</surname><given-names>B.H.</given-names></name>
<name><surname>Seo</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>S.H.</given-names></name>
<name><surname>Lee</surname><given-names>E.</given-names></name>
<name><surname>Choi</surname><given-names>H.</given-names></name>
<name><surname>Kim</surname><given-names>K.H.</given-names></name>
<name><surname>Cho</surname><given-names>E.G.</given-names></name>
<name><surname>Lee</surname><given-names>T.R.</given-names></name>
</person-group><article-title>Novel inhibitory effect of the antidiabetic drug voglibose on melanogenesis</article-title><source>Exp. Dermatol.</source><year>2013</year><volume>22</volume><fpage>541</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1111/exd.12195</pub-id><pub-id pub-id-type="pmid">23879813</pub-id>
</element-citation></ref><ref id="B25-pharmaceuticals-18-00224"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghasemi</surname><given-names>M.</given-names></name>
<name><surname>Turnbull</surname><given-names>T.</given-names></name>
<name><surname>Sebastian</surname><given-names>S.</given-names></name>
<name><surname>Kempson</surname><given-names>I.</given-names></name>
</person-group><article-title>The MTT Assay: Utility, Limitations, Pitfalls, and Interpretation in Bulk and Single-Cell Analysis</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>12827</elocation-id><pub-id pub-id-type="doi">10.3390/ijms222312827</pub-id><pub-id pub-id-type="pmid">34884632</pub-id>
</element-citation></ref><ref id="B26-pharmaceuticals-18-00224"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Madorran</surname><given-names>E.</given-names></name>
<name><surname>Ambro&#x0017e;</surname><given-names>M.</given-names></name>
<name><surname>Knez</surname><given-names>J.</given-names></name>
<name><surname>Sobo&#x0010d;an</surname><given-names>M.</given-names></name>
</person-group><article-title>An Overview of the Current State of Cell Viability Assessment Methods Using OECD Classification</article-title><source>Int. J. Mol. Sci.</source><year>2025</year><volume>26</volume><elocation-id>220</elocation-id><pub-id pub-id-type="doi">10.3390/ijms26010220</pub-id></element-citation></ref><ref id="B27-pharmaceuticals-18-00224"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Snyman</surname><given-names>M.</given-names></name>
<name><surname>Walsdorf</surname><given-names>R.E.</given-names></name>
<name><surname>Wix</surname><given-names>S.N.</given-names></name>
<name><surname>Gill</surname><given-names>J.G.</given-names></name>
</person-group><article-title>The metabolism of melanin synthesis-From melanocytes to melanoma</article-title><source>Pigment Cell Melanoma Res.</source><year>2024</year><volume>37</volume><fpage>438</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1111/pcmr.13165</pub-id><pub-id pub-id-type="pmid">38445351</pub-id>
</element-citation></ref><ref id="B28-pharmaceuticals-18-00224"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>Y.J.</given-names></name>
<name><surname>Hyun</surname><given-names>C.G.</given-names></name>
</person-group><article-title>Mechanistic Insights into the Stimulatory Effect of Melanogenesis of 4-Methylcoumarin Derivatives in B16F10 Melanoma Cells</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>12421</elocation-id><pub-id pub-id-type="doi">10.3390/ijms252212421</pub-id><pub-id pub-id-type="pmid">39596485</pub-id>
</element-citation></ref><ref id="B29-pharmaceuticals-18-00224"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jeon</surname><given-names>H.J.</given-names></name>
<name><surname>Kim</surname><given-names>K.</given-names></name>
<name><surname>Kim</surname><given-names>C.</given-names></name>
<name><surname>Lee</surname><given-names>S.-E.</given-names></name>
</person-group><article-title>Antimelanogenic Effects of Curcumin and Its Dimethoxy Derivatives: Mechanistic Investigation Using B16F10 Melanoma Cells and Zebrafish (<italic toggle="yes">Danio rerio</italic>) Embryos</article-title><source>Foods</source><year>2023</year><volume>12</volume><elocation-id>926</elocation-id><pub-id pub-id-type="doi">10.3390/foods12050926</pub-id><pub-id pub-id-type="pmid">36900442</pub-id>
</element-citation></ref><ref id="B30-pharmaceuticals-18-00224"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>W.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Yu</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>D.</given-names></name>
<name><surname>Li</surname><given-names>P.</given-names></name>
<name><surname>Xing</surname><given-names>R.</given-names></name>
</person-group><article-title>Melanin: Insights into structure, analysis, and biological activities for future development</article-title><source>J. Mater. Chem. B</source><year>2023</year><volume>11</volume><fpage>7528</fpage><lpage>7543</lpage><pub-id pub-id-type="doi">10.1039/D3TB01132A</pub-id><pub-id pub-id-type="pmid">37432655</pub-id>
</element-citation></ref><ref id="B31-pharmaceuticals-18-00224"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Logesh</surname><given-names>R.</given-names></name>
<name><surname>Prasad</surname><given-names>S.R.</given-names></name>
<name><surname>Chipurupalli</surname><given-names>S.</given-names></name>
<name><surname>Robinson</surname><given-names>N.</given-names></name>
<name><surname>Mohankumar</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Natural tyrosinase enzyme inhibitors: A path from melanin to melanoma and its reported pharmacological activities</article-title><source>Biochim. Biophys. Acta. Rev. Cancer.</source><year>2023</year><volume>1878</volume><elocation-id>188968</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbcan.2023.188968</pub-id><pub-id pub-id-type="pmid">37657683</pub-id>
</element-citation></ref><ref id="B32-pharmaceuticals-18-00224"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>S.C.</given-names></name>
<name><surname>Sheu</surname><given-names>M.L.</given-names></name>
<name><surname>Tsai</surname><given-names>Y.C.</given-names></name>
<name><surname>Lin</surname><given-names>Y.C.</given-names></name>
<name><surname>Chang</surname><given-names>C.W.</given-names></name>
<name><surname>Lai</surname><given-names>D.W.</given-names></name>
</person-group><article-title>Attenuation of in vitro and in vivo melanin synthesis using a Chinese herbal medicine through the inhibition of tyrosinase activity</article-title><source>Phytomedicine</source><year>2022</year><volume>95</volume><fpage>153876</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2021.153876</pub-id><pub-id pub-id-type="pmid">34923233</pub-id>
</element-citation></ref><ref id="B33-pharmaceuticals-18-00224"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beltran</surname><given-names>E.</given-names></name>
<name><surname>Serafini</surname><given-names>M.R.</given-names></name>
<name><surname>Alves</surname><given-names>I.A.</given-names></name>
<name><surname>Arag&#x000f3;n Novoa</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Novel Synthesized Tyrosinase Inhibitors: A Systematic Patent Review (2012-Present)</article-title><source>Curr. Med. Chem.</source><year>2024</year><volume>31</volume><fpage>308</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.2174/0929867330666230203111437</pub-id><pub-id pub-id-type="pmid">36740802</pub-id>
</element-citation></ref><ref id="B34-pharmaceuticals-18-00224"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Ma</surname><given-names>W.</given-names></name>
<name><surname>Fan</surname><given-names>D.</given-names></name>
<name><surname>Hu</surname><given-names>J.</given-names></name>
<name><surname>An</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
</person-group><article-title>The biochemistry of melanogenesis: An insight into the function and mechanism of melanogenesis-related proteins</article-title><source>Front. Mol. Biosci.</source><year>2024</year><volume>11</volume><elocation-id>1440187</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2024.1440187</pub-id><pub-id pub-id-type="pmid">39228912</pub-id>
</element-citation></ref><ref id="B35-pharmaceuticals-18-00224"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Emanuelli</surname><given-names>M.</given-names></name>
<name><surname>Sartini</surname><given-names>D.</given-names></name>
<name><surname>Molinelli</surname><given-names>E.</given-names></name>
<name><surname>Campagna</surname><given-names>R.</given-names></name>
<name><surname>Pozzi</surname><given-names>V.</given-names></name>
<name><surname>Salvolini</surname><given-names>E.</given-names></name>
<name><surname>Simonetti</surname><given-names>O.</given-names></name>
<name><surname>Campanati</surname><given-names>A.</given-names></name>
<name><surname>Offidani</surname><given-names>A.</given-names></name>
</person-group><article-title>The Double-Edged Sword of Oxidative Stress in Skin Damage and Melanoma: From Physiopathology to Therapeutical Approaches</article-title><source>Antioxidants</source><year>2022</year><volume>11</volume><elocation-id>612</elocation-id><pub-id pub-id-type="doi">10.3390/antiox11040612</pub-id><pub-id pub-id-type="pmid">35453297</pub-id>
</element-citation></ref><ref id="B36-pharmaceuticals-18-00224"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mo</surname><given-names>X.</given-names></name>
<name><surname>Kazmi</surname><given-names>H.R.</given-names></name>
<name><surname>Preston-Alp</surname><given-names>S.</given-names></name>
<name><surname>Zhou</surname><given-names>B.</given-names></name>
<name><surname>Zaidi</surname><given-names>M.R.</given-names></name>
</person-group><article-title>Interferon-gamma induces melanogenesis via post-translational regulation of tyrosinase</article-title><source>Pigment Cell Melanoma Res.</source><year>2022</year><volume>35</volume><fpage>342</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1111/pcmr.13036</pub-id><pub-id pub-id-type="pmid">35266648</pub-id>
</element-citation></ref><ref id="B37-pharmaceuticals-18-00224"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lavinda</surname><given-names>O.</given-names></name>
<name><surname>Manga</surname><given-names>P.</given-names></name>
<name><surname>Orlow</surname><given-names>S.J.</given-names></name>
<name><surname>Cardozo</surname><given-names>T.</given-names></name>
</person-group><article-title>Biophysical Compatibility of a Heterotrimeric Tyrosinase-TYRP1-TYRP2 Metalloenzyme Complex</article-title><source>Front. Pharmacol.</source><year>2021</year><volume>12</volume><elocation-id>602206</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2021.602206</pub-id><pub-id pub-id-type="pmid">33995009</pub-id>
</element-citation></ref><ref id="B38-pharmaceuticals-18-00224"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>Q.</given-names></name>
<name><surname>Chai</surname><given-names>W.M.</given-names></name>
<name><surname>Ma</surname><given-names>Z.Y.</given-names></name>
<name><surname>Ou-Yang</surname><given-names>C.</given-names></name>
<name><surname>Wei</surname><given-names>Q.M.</given-names></name>
<name><surname>Song</surname><given-names>S.</given-names></name>
<name><surname>Zou</surname><given-names>Z.R.</given-names></name>
<name><surname>Peng</surname><given-names>Y.Y.</given-names></name>
</person-group><article-title>Inhibition of &#x003b1;-glucosidase activity and non-enzymatic glycation by tannic acid: Inhibitory activity and molecular mechanism</article-title><source>Int. J. Biol. Macromol.</source><year>2019</year><volume>141</volume><fpage>358</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2019.09.010</pub-id><pub-id pub-id-type="pmid">31491512</pub-id>
</element-citation></ref><ref id="B39-pharmaceuticals-18-00224"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liang</surname><given-names>Y.Q.</given-names></name>
<name><surname>Wen</surname><given-names>Y.T.</given-names></name>
<name><surname>Fu</surname><given-names>Q.Q.</given-names></name>
<name><surname>Yu</surname><given-names>Z.Y.</given-names></name>
<name><surname>Wang</surname><given-names>L.J.</given-names></name>
<name><surname>Zou</surname><given-names>Z.R.</given-names></name>
<name><surname>Zhu</surname><given-names>D.</given-names></name>
<name><surname>Chai</surname><given-names>W.M.</given-names></name>
</person-group><article-title>Structure analysis and tyrosinase, melanogenesis, &#x003b1;-glucosidase, and nonenzymatic glycation inhibitory activities of polymeric proanthocyanidins from the pulp of <italic toggle="yes">Crataegus pinnatifida</italic> Bge</article-title><source>Ind. Crops Prod.</source><year>2022</year><volume>187</volume><fpage>115524</fpage><pub-id pub-id-type="doi">10.1016/j.indcrop.2022.115524</pub-id></element-citation></ref><ref id="B40-pharmaceuticals-18-00224"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>K.</given-names></name>
<name><surname>Meng</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Zhong</surname><given-names>Z.</given-names></name>
</person-group><article-title>The degradation of TYR variants derived from Chinese OCA families is mediated by the ERAD and ERLAD pathway</article-title><source>Gene</source><year>2025</year><volume>932</volume><fpage>148907</fpage><pub-id pub-id-type="doi">10.1016/j.gene.2024.148907</pub-id><pub-id pub-id-type="pmid">39218412</pub-id>
</element-citation></ref><ref id="B41-pharmaceuticals-18-00224"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ninagawa</surname><given-names>S.</given-names></name>
<name><surname>George</surname><given-names>G.</given-names></name>
<name><surname>Mori</surname><given-names>K.</given-names></name>
</person-group><article-title>Mechanisms of productive folding and endoplasmic reticulum-associated degradation of glycoproteins and non-glycoproteins</article-title><source>Biochim. Biophys. Acta Gen. Subj.</source><year>2021</year><volume>1865</volume><elocation-id>129812</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbagen.2020.129812</pub-id><pub-id pub-id-type="pmid">33316349</pub-id>
</element-citation></ref><ref id="B42-pharmaceuticals-18-00224"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Song</surname><given-names>Q.</given-names></name>
<name><surname>Zheng</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>R.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
</person-group><article-title>Toxicity and Metabolomic Dysfunction Invoked by Febrifugin, a Harmful Component of Edible Nut of <italic toggle="yes">Swietenia macrophylla</italic></article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>9753</elocation-id><pub-id pub-id-type="doi">10.3390/ijms25179753</pub-id><pub-id pub-id-type="pmid">39273700</pub-id>
</element-citation></ref><ref id="B43-pharmaceuticals-18-00224"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garc&#x000ed;a-Villegas</surname><given-names>A.</given-names></name>
<name><surname>Rojas-Garc&#x000ed;a</surname><given-names>A.</given-names></name>
<name><surname>Villegas-Aguilar</surname><given-names>M.D.C.</given-names></name>
<name><surname>Fern&#x000e1;ndez-Moreno</surname><given-names>P.</given-names></name>
<name><surname>Fern&#x000e1;ndez-Ochoa</surname><given-names>&#x000c1;.</given-names></name>
<name><surname>C&#x000e1;diz-Gurrea</surname><given-names>M.L.</given-names></name>
<name><surname>Arr&#x000e1;ez-Rom&#x000e1;n</surname><given-names>D.</given-names></name>
<name><surname>Segura-Carretero</surname><given-names>A.</given-names></name>
</person-group><article-title>Cosmeceutical Potential of Major Tropical and Subtropical Fruit By-Products for a Sustainable Revalorization</article-title><source>Antioxidants</source><year>2022</year><volume>11</volume><elocation-id>203</elocation-id><pub-id pub-id-type="doi">10.3390/antiox11020203</pub-id><pub-id pub-id-type="pmid">35204085</pub-id>
</element-citation></ref><ref id="B44-pharmaceuticals-18-00224"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nakamura</surname><given-names>H.</given-names></name>
<name><surname>Fukuda</surname><given-names>M.</given-names></name>
</person-group><article-title>Establishment of a synchronized tyrosinase transport system revealed a role of Tyrp1 in effiient melanogenesis by promoting tyrosinase targeting to melanosomes</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><elocation-id>2529</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-024-53072-6</pub-id><pub-id pub-id-type="pmid">38291221</pub-id>
</element-citation></ref><ref id="B45-pharmaceuticals-18-00224"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vachtenheim</surname><given-names>J.</given-names></name>
<name><surname>Borovansk&#x000fd;</surname><given-names>J.</given-names></name>
</person-group><article-title>&#x0201c;Transcription physiology&#x0201d; of pigment formation in melanocytes: Central role of MITF</article-title><source>Exp. Dermatol.</source><year>2010</year><volume>19</volume><fpage>617</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0625.2009.01053.x</pub-id><pub-id pub-id-type="pmid">20201954</pub-id>
</element-citation></ref><ref id="B46-pharmaceuticals-18-00224"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gelmi</surname><given-names>M.C.</given-names></name>
<name><surname>Houtzagers</surname><given-names>L.E.</given-names></name>
<name><surname>Strub</surname><given-names>T.</given-names></name>
<name><surname>Krossa</surname><given-names>I.</given-names></name>
<name><surname>Jager</surname><given-names>M.J.</given-names></name>
</person-group><article-title>MITF in Normal Melanocytes, Cutaneous and Uveal Melanoma: A Delicate Balance</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>6001</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23116001</pub-id><pub-id pub-id-type="pmid">35682684</pub-id>
</element-citation></ref><ref id="B47-pharmaceuticals-18-00224"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Arnheiter</surname><given-names>H.</given-names></name>
<name><surname>Hou</surname><given-names>L.</given-names></name>
</person-group><article-title>The transcription factor MITF in RPE function and dysfunction</article-title><source>Prog. Retin. Eye Res.</source><year>2019</year><volume>73</volume><fpage>100766</fpage><pub-id pub-id-type="doi">10.1016/j.preteyeres.2019.06.002</pub-id><pub-id pub-id-type="pmid">31242455</pub-id>
</element-citation></ref><ref id="B48-pharmaceuticals-18-00224"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>S.</given-names></name>
<name><surname>Zeng</surname><given-names>H.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>Lei</surname><given-names>L.</given-names></name>
<name><surname>Tong</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Guo</surname><given-names>H.</given-names></name>
<name><surname>Khan</surname><given-names>M.</given-names></name>
<name><surname>Luo</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Epigenetic regulation of melanogenesis</article-title><source>Ageing Res. Rev.</source><year>2021</year><volume>69</volume><fpage>101349</fpage><pub-id pub-id-type="doi">10.1016/j.arr.2021.101349</pub-id><pub-id pub-id-type="pmid">33984527</pub-id>
</element-citation></ref><ref id="B49-pharmaceuticals-18-00224"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Netcharoensirisuk</surname><given-names>P.</given-names></name>
<name><surname>Umehara</surname><given-names>K.</given-names></name>
<name><surname>De-Eknamkul</surname><given-names>W.</given-names></name>
<name><surname>Chaotham</surname><given-names>C.</given-names></name>
</person-group><article-title>Cajanin Suppresses Melanin Synthesis through Modulating MITF in Human Melanin-Producing Cells</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>6040</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26196040</pub-id><pub-id pub-id-type="pmid">34641584</pub-id>
</element-citation></ref><ref id="B50-pharmaceuticals-18-00224"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pillaiyar</surname><given-names>T.</given-names></name>
<name><surname>Manickam</surname><given-names>M.</given-names></name>
<name><surname>Jung</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Recent development of signaling pathways inhibitors of melanogenesis</article-title><source>Cell. Signal.</source><year>2017</year><volume>40</volume><fpage>99</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2017.09.004</pub-id><pub-id pub-id-type="pmid">28911859</pub-id>
</element-citation></ref><ref id="B51-pharmaceuticals-18-00224"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pillaiyar</surname><given-names>T.</given-names></name>
<name><surname>Manickam</surname><given-names>M.</given-names></name>
<name><surname>Jung</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Downregulation of melanogenesis: Drug discovery and therapeutic options</article-title><source>Drug Discov. Today</source><year>2017</year><volume>22</volume><fpage>282</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2016.09.016</pub-id><pub-id pub-id-type="pmid">27693716</pub-id>
</element-citation></ref><ref id="B52-pharmaceuticals-18-00224"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qian</surname><given-names>W.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Zhu</surname><given-names>D.</given-names></name>
<name><surname>Cao</surname><given-names>Y.</given-names></name>
<name><surname>Tang</surname><given-names>A.</given-names></name>
<name><surname>Gong</surname><given-names>G.</given-names></name>
<name><surname>Su</surname><given-names>H.</given-names></name>
</person-group><article-title>Natural skin-whitening compounds for the treatment of melanogenesis (Review)</article-title><source>Exp. Ther. Med.</source><year>2020</year><volume>20</volume><fpage>173</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.3892/etm.2020.8687</pub-id></element-citation></ref><ref id="B53-pharmaceuticals-18-00224"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Sun</surname><given-names>G.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Zhai</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Ma</surname><given-names>R.</given-names></name>
<name><surname>Zhao</surname><given-names>D.</given-names></name>
<name><surname>Jiang</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Phenolic acids in Panax ginseng inhibit melanin production through bidirectional regulation of melanin synthase transcription via different signaling pathways</article-title><source>J. Ginseng Res.</source><year>2023</year><volume>47</volume><fpage>714</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1016/j.jgr.2023.05.002</pub-id><pub-id pub-id-type="pmid">38107393</pub-id>
</element-citation></ref><ref id="B54-pharmaceuticals-18-00224"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>T.</given-names></name>
<name><surname>Kang</surname><given-names>J.K.</given-names></name>
<name><surname>Hyun</surname><given-names>C.G.</given-names></name>
</person-group><article-title>6-Methylcoumarin Promotes Melanogenesis through the PKA/CREB, MAPK, AKT/PI3K, and GSK3&#x003b2;/&#x003b2;-Catenin Signaling Pathways</article-title><source>Molecules</source><year>2023</year><volume>28</volume><elocation-id>4551</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28114551</pub-id><pub-id pub-id-type="pmid">37299026</pub-id>
</element-citation></ref><ref id="B55-pharmaceuticals-18-00224"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Han</surname><given-names>H.</given-names></name>
<name><surname>Hyun</surname><given-names>C.G.</given-names></name>
</person-group><article-title>Syringetin Promotes Melanogenesis in B16F10 Cells</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>9960</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24129960</pub-id><pub-id pub-id-type="pmid">37373110</pub-id>
</element-citation></ref><ref id="B56-pharmaceuticals-18-00224"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>S.</given-names></name>
<name><surname>Han</surname><given-names>N.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>J.N.</given-names></name>
<name><surname>An</surname><given-names>S.</given-names></name>
<name><surname>Bae</surname><given-names>S.</given-names></name>
</person-group><article-title>Anti-Melanogenic Effects of <italic toggle="yes">Lilium lancifolium</italic> Root Extract via Downregulation of PKA/CREB and MAPK/CREB Signaling Pathways in B16F10 Cells</article-title><source>Plants</source><year>2023</year><volume>12</volume><elocation-id>3666</elocation-id><pub-id pub-id-type="doi">10.3390/plants12213666</pub-id><pub-id pub-id-type="pmid">37960022</pub-id>
</element-citation></ref><ref id="B57-pharmaceuticals-18-00224"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>S.</given-names></name>
<name><surname>Sakamoto</surname><given-names>K.</given-names></name>
</person-group><article-title>Citric acid promoted melanin synthesis in B16F10 mouse melanoma cells, but inhibited it in human epidermal melanocytes and HMV-II melanoma cells via the GSK3&#x003b2;/&#x003b2;-catenin signaling pathway</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><elocation-id>e0243565</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0243565</pub-id><pub-id pub-id-type="pmid">33332393</pub-id>
</element-citation></ref><ref id="B58-pharmaceuticals-18-00224"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Noh</surname><given-names>T.K.</given-names></name>
<name><surname>Bang</surname><given-names>S.H.</given-names></name>
<name><surname>Lee</surname><given-names>Y.J.</given-names></name>
<name><surname>Cho</surname><given-names>H.I.</given-names></name>
<name><surname>Jung</surname><given-names>M.Y.</given-names></name>
<name><surname>Kim</surname><given-names>I.</given-names></name>
<name><surname>Leem</surname><given-names>C.H.</given-names></name>
<name><surname>Chang</surname><given-names>S.E.</given-names></name>
</person-group><article-title>The ion channel activator CyPPA inhibits melanogenesis via the GSK3&#x003b2;/&#x003b2;-catenin pathway</article-title><source>Chem. Biol. Interact.</source><year>2019</year><volume>300</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2018.12.014</pub-id><pub-id pub-id-type="pmid">30597128</pub-id>
</element-citation></ref><ref id="B59-pharmaceuticals-18-00224"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>F.</given-names></name>
<name><surname>Kong</surname><given-names>X.</given-names></name>
<name><surname>Kong</surname><given-names>H.</given-names></name>
</person-group><article-title>Ethylparaben induces subconjunctival fibrosis via the Wnt/&#x003b2;-catenin signaling pathway</article-title><source>Exp. Ther. Med.</source><year>2021</year><volume>21</volume><fpage>295</fpage><pub-id pub-id-type="doi">10.3892/etm.2021.9726</pub-id><pub-id pub-id-type="pmid">33717238</pub-id>
</element-citation></ref><ref id="B60-pharmaceuticals-18-00224"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cao</surname><given-names>Y.</given-names></name>
<name><surname>Lv</surname><given-names>J.</given-names></name>
<name><surname>Tan</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>R.</given-names></name>
<name><surname>Jiang</surname><given-names>X.</given-names></name>
<name><surname>Meng</surname><given-names>D.</given-names></name>
<name><surname>Zou</surname><given-names>K.</given-names></name>
<name><surname>Pan</surname><given-names>M.</given-names></name>
<name><surname>Tang</surname><given-names>L.</given-names></name>
</person-group><article-title>Tribuloside acts on the PDE/cAMP/PKA pathway to enhance melanogenesis, melanocyte dendricity and melanosome transport</article-title><source>J. Ethnopharmacol.</source><year>2024</year><volume>323</volume><fpage>117673</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2023.117673</pub-id><pub-id pub-id-type="pmid">38158096</pub-id>
</element-citation></ref><ref id="B61-pharmaceuticals-18-00224"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Jiang</surname><given-names>S.</given-names></name>
<name><surname>Huang</surname><given-names>C.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
</person-group><article-title>Atraric Acid Ameliorates Hyperpigmentation through the Downregulation of the PKA/CREB/MITF Signaling Pathway</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>15952</elocation-id><pub-id pub-id-type="doi">10.3390/ijms232415952</pub-id><pub-id pub-id-type="pmid">36555593</pub-id>
</element-citation></ref><ref id="B62-pharmaceuticals-18-00224"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lim</surname><given-names>H.Y.</given-names></name>
<name><surname>Kim</surname><given-names>E.</given-names></name>
<name><surname>Park</surname><given-names>S.H.</given-names></name>
<name><surname>Hwang</surname><given-names>K.H.</given-names></name>
<name><surname>Kim</surname><given-names>D.</given-names></name>
<name><surname>Jung</surname><given-names>Y.J.</given-names></name>
<name><surname>Kopalli</surname><given-names>S.R.</given-names></name>
<name><surname>Hong</surname><given-names>Y.D.</given-names></name>
<name><surname>Sung</surname><given-names>G.H.</given-names></name>
<name><surname>Cho</surname><given-names>J.Y.</given-names></name>
</person-group><article-title>Antimelanogenesis Effects of Theasinensin A</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>7453</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22147453</pub-id><pub-id pub-id-type="pmid">34299073</pub-id>
</element-citation></ref><ref id="B63-pharmaceuticals-18-00224"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.H.</given-names></name>
<name><surname>Hwang</surname><given-names>S.J.</given-names></name>
<name><surname>Lee</surname><given-names>S.K.</given-names></name>
<name><surname>Choi</surname><given-names>Y.</given-names></name>
<name><surname>Byun</surname><given-names>C.K.</given-names></name>
<name><surname>Son</surname><given-names>C.G.</given-names></name>
</person-group><article-title>Anti-Melanogenic Effects of Fractioned <italic toggle="yes">Cynanchum atratum</italic> by Regulation of cAMP/MITF Pathway in a UVB-Stimulated Mice Model</article-title><source>Cells</source><year>2023</year><volume>12</volume><elocation-id>1390</elocation-id><pub-id pub-id-type="doi">10.3390/cells12101390</pub-id><pub-id pub-id-type="pmid">37408224</pub-id>
</element-citation></ref><ref id="B64-pharmaceuticals-18-00224"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yin</surname><given-names>L.</given-names></name>
<name><surname>Niu</surname><given-names>C.</given-names></name>
<name><surname>Liao</surname><given-names>L.X.</given-names></name>
<name><surname>Dou</surname><given-names>J.</given-names></name>
<name><surname>Habasi</surname><given-names>M.</given-names></name>
<name><surname>Aisa</surname><given-names>H.A.</given-names></name>
</person-group><article-title>An Isoxazole Chalcone Derivative Enhances Melanogenesis in B16 Melanoma Cells via the Akt/GSK3&#x003b2;/&#x003b2;-Catenin Signaling Pathways</article-title><source>Molecules</source><year>2017</year><volume>22</volume><elocation-id>2077</elocation-id><pub-id pub-id-type="doi">10.3390/molecules22122077</pub-id><pub-id pub-id-type="pmid">29182558</pub-id>
</element-citation></ref><ref id="B65-pharmaceuticals-18-00224"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Niu</surname><given-names>C.</given-names></name>
<name><surname>Yin</surname><given-names>L.</given-names></name>
<name><surname>Aisa</surname><given-names>H.A.</given-names></name>
</person-group><article-title>Novel Furocoumarin Derivatives Stimulate Melanogenesis in B16 Melanoma Cells by Up-Regulation of MITF and TYR Family via Akt/GSK3&#x003b2;/&#x003b2;-Catenin Signaling Pathways</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>746</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19030746</pub-id><pub-id pub-id-type="pmid">29509689</pub-id>
</element-citation></ref><ref id="B66-pharmaceuticals-18-00224"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zang</surname><given-names>D.</given-names></name>
<name><surname>Niu</surname><given-names>C.</given-names></name>
<name><surname>Aisa</surname><given-names>H.A.</given-names></name>
</person-group><article-title>Amine derivatives of furocoumarin induce melanogenesis by activating Akt/GSK-3&#x003b2;/&#x003b2;-catenin signal pathway</article-title><source>Drug Des. Dev. Ther.</source><year>2019</year><volume>13</volume><fpage>623</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S180960</pub-id></element-citation></ref><ref id="B67-pharmaceuticals-18-00224"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhat</surname><given-names>A.M.</given-names></name>
<name><surname>Haroon</surname><given-names>R.</given-names></name>
<name><surname>Naikoo</surname><given-names>S.</given-names></name>
<name><surname>Sharma</surname><given-names>R.R.</given-names></name>
<name><surname>Archoo</surname><given-names>S.</given-names></name>
<name><surname>Tasduq</surname><given-names>S.A.</given-names></name>
</person-group><article-title>(2-Methylbutyryl)shikonin Naturally Occurring Shikonin Derivative Ameliorates the &#x003b1;-MSH-Induced Melanogenesis via ERK1/2 and p38 MAP Kinase-Mediated Down-Regulation of the MITF Transcription Factor</article-title><source>Chem. Res. Toxicol.</source><year>2024</year><volume>37</volume><fpage>274</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrestox.3c00283</pub-id><pub-id pub-id-type="pmid">38271289</pub-id>
</element-citation></ref><ref id="B68-pharmaceuticals-18-00224"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shin</surname><given-names>S.</given-names></name>
<name><surname>Ko</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>M.</given-names></name>
<name><surname>Song</surname><given-names>N.</given-names></name>
<name><surname>Park</surname><given-names>K.</given-names></name>
</person-group><article-title>Morin Induces Melanogenesis via Activation of MAPK Signaling Pathways in B16F10 Mouse Melanoma Cells</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>2150</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26082150</pub-id><pub-id pub-id-type="pmid">33917985</pub-id>
</element-citation></ref><ref id="B69-pharmaceuticals-18-00224"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Zeng</surname><given-names>H.L.</given-names></name>
<name><surname>Wen</surname><given-names>X.Y.</given-names></name>
<name><surname>Jiang</surname><given-names>L.</given-names></name>
<name><surname>Fu</surname><given-names>C.H.</given-names></name>
<name><surname>Hu</surname><given-names>Y.B.</given-names></name>
<name><surname>Lei</surname><given-names>X.X.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Yu</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>S.Y.</given-names></name>
<etal/>
</person-group><article-title>Selaginellin Inhibits Melanogenesis via the MAPK Signaling Pathway</article-title><source>J. Nat. Prod.</source><year>2022</year><volume>85</volume><fpage>838</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.1c00971</pub-id><pub-id pub-id-type="pmid">35290062</pub-id>
</element-citation></ref><ref id="B70-pharmaceuticals-18-00224"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chung</surname><given-names>Y.C.</given-names></name>
<name><surname>Lee</surname><given-names>J.N.</given-names></name>
<name><surname>Kim</surname><given-names>B.S.</given-names></name>
<name><surname>Hyun</surname><given-names>C.G.</given-names></name>
</person-group><article-title>Anti-Melanogenic Effects of <italic toggle="yes">Paederia foetida</italic> L. Extract via MAPK Signaling-Mediated MITF Downregulation</article-title><source>Cosmetics</source><year>2021</year><volume>8</volume><elocation-id>22</elocation-id><pub-id pub-id-type="doi">10.3390/cosmetics8010022</pub-id></element-citation></ref><ref id="B71-pharmaceuticals-18-00224"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>B.</given-names></name>
</person-group><article-title>Application of an in vitro reconstructed human skin on cosmetics in skin irritation tests</article-title><source>J. Cosmet. Dermatol.</source><year>2021</year><volume>20</volume><fpage>1933</fpage><lpage>1941</lpage><pub-id pub-id-type="doi">10.1111/jocd.13789</pub-id><pub-id pub-id-type="pmid">33053260</pub-id>
</element-citation></ref><ref id="B72-pharmaceuticals-18-00224"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patrick</surname><given-names>M.</given-names></name>
<name><surname>Gallic</surname><given-names>B.</given-names></name>
<name><surname>Laurent</surname><given-names>P.M.</given-names></name>
<name><surname>Elian</surname><given-names>L.</given-names></name>
<name><surname>Richard</surname><given-names>F.</given-names></name>
<name><surname>Katell</surname><given-names>V.</given-names></name>
</person-group><article-title>Assessment of an ex vivo irritation test performed on human skin explants and comparison of its results with those of a 24-/48-h human patch test for the evaluation of cosmetics</article-title><source>Toxicol. In Vitro</source><year>2021</year><volume>70</volume><fpage>105030</fpage><pub-id pub-id-type="doi">10.1016/j.tiv.2020.105030</pub-id><pub-id pub-id-type="pmid">33058998</pub-id>
</element-citation></ref><ref id="B73-pharmaceuticals-18-00224"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nordin</surname><given-names>F.N.M.</given-names></name>
<name><surname>Aziz</surname><given-names>A.</given-names></name>
<name><surname>Zakaria</surname><given-names>Z.</given-names></name>
<name><surname>Wan Mohamed Radzi</surname><given-names>C.W.J.</given-names></name>
</person-group><article-title>A systematic review on the skin whitening products and their ingredients for safety, health risk, and the halal status</article-title><source>J. Cosmet. Dermatol.</source><year>2021</year><volume>20</volume><fpage>1050</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1111/jocd.13691</pub-id><pub-id pub-id-type="pmid">32854162</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceuticals-18-00224-f001"><label>Figure 1</label><caption><p>The structure of voglibose.</p></caption><graphic xlink:href="pharmaceuticals-18-00224-g001" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00224-f002"><label>Figure 2</label><caption><p>The effects of voglibose on cell viability, melanin production, and tyrosinase activity in B16F10 cells. Cell viability was assessed under two conditions. In (<bold>a</bold>), cells were plated at 1.0 &#x000d7; 10<sup>5</sup> cells/well and treated with voglibose for 24 h. In (<bold>b</bold>), cells were plated at 2.0 &#x000d7; 10<sup>4</sup> cells/well and treated for 72 h. Cell viability was expressed as a percentage relative to untreated cells. Voglibose treatment reduced melanin content (<bold>c</bold>) and tyrosinase activity (<bold>d</bold>) in B16F10 cells. &#x003b1;-melanocyte-stimulating hormone (&#x003b1;-MSH) was used as a negative control to induce melanogenesis, and arbutin was used as a positive control to inhibit it. A cell viability assay was performed in triplicate (<italic toggle="yes">n</italic> = 3), and all data are presented as the mean &#x000b1; standard deviation (SD) from at least three independent experiments. Statistical significance was denoted as *** <italic toggle="yes">p</italic> &#x0003c; 0.001 vs. the untreated control or the &#x003b1;-MSH-only group and # <italic toggle="yes">p</italic> &#x0003c; 0.001 compared to the untreated group.</p></caption><graphic xlink:href="pharmaceuticals-18-00224-g002a" position="float"/><graphic xlink:href="pharmaceuticals-18-00224-g002b" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00224-f003"><label>Figure 3</label><caption><p>The effects of voglibose on melanogenic proteins and the expression of the transcription factor MITF in B16F10 cells. (<bold>a</bold>) The Western blot results illustrating the expression changes of tyrosinase (TYR), TRP-1, TRP-2, and MITF, a key transcription factor regulating melanogenesis. (<bold>b</bold>&#x02013;<bold>e</bold>) Quantitative graphs of TRP-1, TRP-2, tyrosinase, and MITF protein expression visually depicting the effects of voglibose treatment on protein expression. &#x003b1;-MSH (100 nM) was used to induce melanogenesis, and statistical significance is denoted as # <italic toggle="yes">p</italic> &#x0003c; 0.001 compared to the untreated control and ** <italic toggle="yes">p</italic> &#x0003c; 0.01 or *** <italic toggle="yes">p</italic> &#x0003c; 0.001 compared to the &#x003b1;-MSH-only group. Data are expressed as the mean &#x000b1; standard deviation (SD) from at least three independent experiments, each performed in triplicate, and analyzed using ImageJ software (version 1.54k, NIH, Bethesda, MD, USA).</p></caption><graphic xlink:href="pharmaceuticals-18-00224-g003a" position="float"/><graphic xlink:href="pharmaceuticals-18-00224-g003b" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00224-f004"><label>Figure 4</label><caption><p>The relationship between the anti-melanogenic effects of voglibose and the Wnt/&#x003b2;-catenin signaling pathway in B16F10 cells. (<bold>a</bold>) The Western blot results for phosphorylated GSK3&#x003b2; (p-GSK3&#x003b2;), total GSK3&#x003b2;, phosphorylated &#x003b2;-catenin (p-&#x003b2;-catenin), and total &#x003b2;-catenin, normalized to &#x003b2;-actin as the loading control. (<bold>b</bold>&#x02013;<bold>d</bold>) Quantitative analyses of protein expression levels, highlighting the dose-dependent effects of voglibose. Voglibose treatment increased p-&#x003b2;-catenin expression (<bold>b</bold>) while decreasing total &#x003b2;-catenin levels (<bold>c</bold>) and reducing p-GSK3&#x003b2; expression (<bold>d</bold>). These results indicate that voglibose restores GSK3&#x003b2; activity, promotes &#x003b2;-catenin degradation, and modulates the Wnt/&#x003b2;-catenin signaling pathway. &#x003b1;-MSH (100 nM) was used to induce melanogenesis, and statistical significance is denoted as # <italic toggle="yes">p</italic> &#x0003c; 0.001 compared to the untreated control and *** <italic toggle="yes">p</italic> &#x0003c; 0.001 compared to the &#x003b1;-MSH-only group. Data are expressed as the mean &#x000b1; SD from at least three independent triplicate experiments and analyzed using ImageJ software version 1.54k (NIH, Bethesda, MD, USA).</p></caption><graphic xlink:href="pharmaceuticals-18-00224-g004" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00224-f005"><label>Figure 5</label><caption><p>The relationship between the anti-melanogenic effects of voglibose and the PKA/CREB signaling pathway in B16F10 cells. (<bold>a</bold>) The Western blot results for phosphorylated PKA (p-PKA), total PKA (t-PKA), phosphorylated CREB (p-CREB), and total CREB (t-CREB), with &#x003b2;-actin used as a loading control. (<bold>b</bold>,<bold>c</bold>) Quantitative analyses of protein expression levels, demonstrating the dose-dependent effects of voglibose. Voglibose treatment reduced p-PKA expression (<bold>b</bold>) and p-CREB expression (<bold>c</bold>), indicating its inhibitory effect on the PKA/CREB pathway. Statistical significance is denoted as <italic toggle="yes"># p</italic> &#x0003c; 0.001 compared to the untreated control and *** <italic toggle="yes">p</italic> &#x0003c; 0.001 compared to the &#x003b1;-MSH-only group. Data are expressed as the mean &#x000b1; SD from at least three independent triplicate experiments and analyzed using ImageJ software (version 1.54k; NIH, Bethesda, MD, USA).</p></caption><graphic xlink:href="pharmaceuticals-18-00224-g005a" position="float"/><graphic xlink:href="pharmaceuticals-18-00224-g005b" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00224-f006"><label>Figure 6</label><caption><p>The relationship between the anti-melanogenic effects of voglibose and the AKT signaling pathway in B16F10 cells. (<bold>a</bold>) The Western blot results for phosphorylated AKT (p-AKT) and total AKT (t-AKT), with &#x003b2;-actin used as a loading control. (<bold>b</bold>) Quantitative analysis of p-AKT expression, demonstrating the dose-dependent effects of voglibose treatment. Voglibose significantly reduced p-AKT expression, indicating its inhibitory effect on the AKT signaling pathway. &#x003b1;-MSH (100 nM) was used to induce melanogenesis, and statistical significance is denoted as # <italic toggle="yes">p</italic> &#x0003c; 0.001 compared to the untreated control and *** <italic toggle="yes">p</italic> &#x0003c; 0.001 compared to the &#x003b1;-MSH-only group. Data are expressed as the mean &#x000b1; SD from at least three independent triplicate experiments and analyzed using ImageJ software version 1.54k (NIH, Bethesda, MD, USA).</p></caption><graphic xlink:href="pharmaceuticals-18-00224-g006" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00224-f007"><label>Figure 7</label><caption><p>The relationship between the anti-melanogenic effects of voglibose and the MAPK signaling pathway in B16F10 cells. (<bold>a</bold>) The Western blot results for phosphorylated and total ERK, p38, and JNK proteins, normalized to &#x003b2;-actin as the loading control. (<bold>b</bold>&#x02013;<bold>d</bold>) Quantitative analyses of protein expression levels, demonstrating the dose-dependent effects of voglibose treatment. Voglibose treatment increased p-ERK expression (<bold>b</bold>) while significantly decreasing p-JNK (<bold>c</bold>) and p-p38 (<bold>d</bold>) expression levels, indicating its modulatory effects on the MAPK signaling pathway. &#x003b1;-MSH (100 nM) was used to induce melanogenesis, and statistical significance is denoted as # <italic toggle="yes">p</italic> &#x0003c; 0.001 compared to the untreated control and *** <italic toggle="yes">p</italic> &#x0003c; 0.001 compared to the &#x003b1;-MSH-only group. Data are expressed as the mean &#x000b1; SD from at least three independent triplicate experiments and analyzed using ImageJ software (version 1.54k, NIH, Bethesda, MD, USA).</p></caption><graphic xlink:href="pharmaceuticals-18-00224-g007" position="float"/></fig><table-wrap position="float" id="pharmaceuticals-18-00224-t001"><object-id pub-id-type="pii">pharmaceuticals-18-00224-t001_Table 1</object-id><label>Table 1</label><caption><p>The results from the primary human skin irritation tests (<italic toggle="yes">n</italic> = 33).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">No.</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Sample</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Respondents</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">20 min After Removal</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">24 h After Removal</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Reaction<break/>Grade (R) <italic toggle="yes">*</italic></th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+1</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+2</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+3</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+4</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+1</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+2</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+3</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+4</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 h</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48 h</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Voglibose (50 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Voglibose (100 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Squalene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn><p>The reactions were assessed at 20 min and 24 h after the removal of the treatment by the investigator, according to the PCPC guidelines. * The range of irritation from &#x0201c;no to slight irritation&#x0201d;: 0.00 &#x02264; <italic toggle="yes">R</italic> &#x0003c; 0.87.</p></fn></table-wrap-foot></table-wrap></floats-group></article>